[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 860
1. Sales KJ, Grant V, Jabbour HN: Prostaglandin E2 and F2alpha activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response element. Mol Cell Endocrinol; 2008 Mar 26;285(1-2):51-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In endometrial adenocarcinomas COX-2 and F-series prostanoid (FP) receptor expression and prostanoid biosynthesis (PGE(2) and PGF(2alpha)) are elevated.
  • In the present study, we investigated the effect of PGE(2) and PGF(2alpha) on the expression of COX-2 via the FP receptor in endometrial adenocarcinoma cells stably expressing the FP receptor (FPS cells).
  • These data indicate that PGE(2) and PGF(2alpha) biosynthesized locally within endometrial adenocarcinomas can regulate tumor cell function in an autocrine/paracrine manner via the FP receptor.
  • [MeSH-minor] Adenocarcinoma / metabolism. Cell Line, Tumor. Endometrial Neoplasms / metabolism. Enzyme Activation. Enzyme Inhibitors / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. Genes, Reporter. Humans. Inositol 1,4,5-Trisphosphate / metabolism. Promoter Regions, Genetic. Prostaglandin Antagonists / metabolism. Receptors, Prostaglandin / antagonists & inhibitors. Receptors, Prostaglandin / genetics. Receptors, Prostaglandin / metabolism. Receptors, Prostaglandin E / metabolism. Xanthones / metabolism

  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):49954-64 [14517215.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):506-11 [11809702.001]
  • [Cites] Mol Endocrinol. 2004 Jun;18(6):1533-45 [15044590.001]
  • [Cites] Trends Endocrinol Metab. 2004 Oct;15(8):398-404 [15380812.001]
  • [Cites] Am J Obstet Gynecol. 1978 Mar 15;130(6):640-6 [637076.001]
  • [Cites] Br J Obstet Gynaecol. 1981 Apr;88(4):434-42 [7225303.001]
  • [Cites] Br J Obstet Gynaecol. 1983 Dec;90(12):1135-40 [6580910.001]
  • [Cites] Br J Obstet Gynaecol. 1984 Jul;91(7):673-80 [6589016.001]
  • [Cites] Br J Obstet Gynaecol. 1988 Feb;95(2):162-5 [2894838.001]
  • [Cites] J Pharmacol Exp Ther. 1990 Nov;255(2):756-68 [2147038.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2522-30 [11980644.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18649-57 [11901151.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31 [12242329.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12151-6 [12566441.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35451-7 [12824187.001]
  • [Cites] Life Sci. 2003 Dec 5;74(2-3):143-53 [14607241.001]
  • [Cites] Reproduction. 2003 Nov;126(5):559-67 [14611628.001]
  • [Cites] J Biol Chem. 1991 Aug 25;266(24):15771-81 [1874734.001]
  • [Cites] J Biol Chem. 1993 Feb 5;268(4):2712-8 [8381413.001]
  • [Cites] Prostaglandins. 1993 May;45(5):413-26 [8321911.001]
  • [Cites] J Biol Chem. 1994 Jul 1;269(26):17619-25 [8021271.001]
  • [Cites] Mol Pharmacol. 1994 Sep;46(3):477-84 [7935328.001]
  • [Cites] J Biol Chem. 1995 Nov 17;270(46):27489-94 [7499206.001]
  • [Cites] Biochem Pharmacol. 1995 Nov 9;50(10):1731-3 [7503778.001]
  • [Cites] Biol Chem Hoppe Seyler. 1996 Jun;377(6):373-84 [8839983.001]
  • [Cites] Gastroenterol Clin North Am. 1996 Dec;25(4):773-91 [8960892.001]
  • [Cites] J Histochem Cytochem. 1998 Jan;46(1):77-84 [9405496.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):455-60 [9521170.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3914-9 [9520467.001]
  • [Cites] J Biol Chem. 1998 Apr 10;273(15):8890-6 [9535870.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] Int J Tissue React. 1998;20(1):3-15 [9561441.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:97-120 [9597150.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):22903-6 [10438452.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Sep;290(3):1278-84 [10454504.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1193-226 [10508233.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6112-8 [15579767.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7707-16 [16140938.001]
  • [Cites] Endocrinology. 2005 Nov;146(11):4657-64 [16081631.001]
  • [Cites] Curr Pharm Des. 2006;12(8):943-54 [16533161.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1697-705 [16373414.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1391-9 [16614756.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14507-12 [16973753.001]
  • [Cites] Curr Opin Investig Drugs. 2007 May;8(5):411-5 [17520870.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3635-44 [17478553.001]
  • [Cites] Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93 [10634944.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):543-50 [10753183.001]
  • [Cites] Cancer Lett. 2000 Aug 1;156(1):57-61 [10840160.001]
  • [Cites] Annu Rev Biochem. 2000;69:145-82 [10966456.001]
  • [Cites] Urology. 2000 Oct 1;56(4):671-6 [11018637.001]
  • [Cites] Trends Endocrinol Metab. 2000 Apr;11(3):91-9 [10707049.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2243-9 [11344234.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18075-81 [11278548.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1023-31 [11592775.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):28-32 [11782353.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):424-32 [11809691.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):986-93 [14764825.001]
  • (PMID = 18316157.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127684438; United Kingdom / Medical Research Council / / U.1276.00.004.00002.01/2(61014)
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / AL 8810; 0 / Enzyme Inhibitors; 0 / Prostaglandin Antagonists; 0 / Receptors, Prostaglandin; 0 / Receptors, Prostaglandin E; 0 / Xanthones; 0 / prostaglandin F2alpha receptor; 33458-93-4 / 6-isopropoxy-9-oxoxanthene-2-carboxylic acid; 85166-31-0 / Inositol 1,4,5-Trisphosphate; B7IN85G1HY / Dinoprost; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC2694994; NLM/ UKMS2447
  •  go-up   go-down


2. van der Horst C, Evans AJ: Peritoneal keratin granulomas complicating endometrial carcinoma: a report of two cases and review of the literature. Int J Gynecol Cancer; 2008 May-Jun;18(3):549-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal keratin granulomas complicating endometrial carcinoma: a report of two cases and review of the literature.
  • Squamous differentiation in endometrial adenocarcinoma is common.
  • Keratin granulomas accompanied by viable adenocarcinoma cells are regarded as conventional metastatic foci.
  • However, the significance of keratin granulomas without accompanying viable adenocarcinoma cells is difficult to ascertain.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Granuloma / pathology. Keratins / metabolism. Peritoneal Diseases / pathology

  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645505.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 8
  •  go-up   go-down


3. Tang WY, Newbold R, Mardilovich K, Jefferson W, Cheng RY, Medvedovic M, Ho SM: Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. Endocrinology; 2008 Dec;149(12):5922-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neonatal exposure of CD-1 mice to diethylstilbestrol (DES) or genistein (GEN) induces uterine adenocarcinoma in aging animals.
  • Uterine carcinogenesis in this model is ovarian dependent because its evolution is blocked by prepubertal ovariectomy.
  • This study seeks to discover novel uterine genes whose expression is altered by such early endocrine disruption via an epigenetic mechanism.
  • Neonatal mice were treated with 1 or 1000 microg/kg DES, 50 mg/kg GEN, or oil (control) on d 1-5.
  • Methylation-sensitive restriction fingerprinting was performed to identify differentially methylated sequences associated with neonatal exposure to DES/GEN.
  • In contrast, in neonatal DES/GEN-treated mice, the Nsbp1 CGI stayed anomalously hypomethylated, and the gene exhibited persistent overexpression throughout life.
  • However, if neonatal DES/GEN-treated mice were ovariectomized before puberty, the CGI remained minimally to moderately methylated, and gene expression was subdued except in the group treated with 1000 microg/kg DES.
  • Thus, the life reprogramming of uterine Nsbp1 expression by neonatal DES/GEN exposure appears to be mediated by an epigenetic mechanism that interacts with ovarian hormones in adulthood.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2000 Feb;127(3):549-58 [10631176.001]
  • [Cites] J Biol Chem. 2000 Dec 1;275(48):37937-44 [10973947.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jan;125(1):146-51 [11151069.001]
  • [Cites] Cancer Causes Control. 2002 Oct;13(8):753-8 [12420954.001]
  • [Cites] J Midwifery Womens Health. 2003 Jan-Feb;48(1):19-29 [12589302.001]
  • [Cites] Biochem Cell Biol. 2003 Jun;81(3):113-22 [12897844.001]
  • [Cites] Mol Carcinog. 2003 Oct;38(2):78-84 [14502647.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):250-9 [14712230.001]
  • [Cites] J Reprod Med. 2004 Feb;49(2):71-5 [15018431.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2003-12 [15161636.001]
  • [Cites] N Engl J Med. 1971 Apr 15;284(15):878-81 [5549830.001]
  • [Cites] Obstet Gynecol. 1972 Sep;40(3):287-98 [5054957.001]
  • [Cites] Pediatrics. 1976 Oct;58(4):505-7 [972792.001]
  • [Cites] Cancer Detect Prev. 1987;10(3-4):237-46 [3568022.001]
  • [Cites] J Toxicol Environ Health. 1990 Jun;30(2):105-22 [2355401.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7677-81 [2174729.001]
  • [Cites] Pediatrics. 1994 Nov;94(5):752-4 [7936913.001]
  • [Cites] J Nutr. 1995 Mar;125(3 Suppl):771S-776S [7884563.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):778-88 [7717601.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1996;54:35-100 [8768072.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1030-4 [9067264.001]
  • [Cites] Mol Cell Biol. 1997 Oct;17(10):5843-55 [9315642.001]
  • [Cites] Lancet. 1997 Oct 4;350(9083):971-2 [9329507.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4356-9 [9331098.001]
  • [Cites] Oncol Rep. 1999 Sep-Oct;6(5):1089-95 [10425307.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):632-6 [15581975.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):166-70 [15790453.001]
  • [Cites] Bioinformatics. 2005 Nov 1;21(21):4067-8 [16141249.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2006 Mar;20(1):63-75 [16522520.001]
  • [Cites] Gynecol Oncol. 2006 Jun;101(3):545-7 [16487996.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5624-32 [16740699.001]
  • [Cites] Genomics. 2001 Jan 15;71(2):163-73 [11161810.001]
  • [Cites] Pediatrics. 1998 Jan;101(1 Pt 1):148-53 [11345979.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4325-8 [11389053.001]
  • [Cites] Mol Carcinog. 2001 Dec;32(4):213-9 [11746833.001]
  • [Cites] J Nutr. 2002 Mar;132(3):552S-558S [11880592.001]
  • [Cites] J Nutr. 2002 Mar;132(3):559S-565S [11880593.001]
  • [Cites] Lancet. 2002 Mar 30;359(9312):1102-7 [11943257.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1089:1-13 [17261752.001]
  • [Cites] APMIS. 2007 Mar;115(3):204-9 [17367465.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2007 May;10(3):360-5 [17414508.001]
  • [Cites] Reprod Toxicol. 2007 Apr-May;23(3):308-16 [17250991.001]
  • [Cites] Reprod Toxicol. 2007 Apr-May;23(3):267-82 [17317097.001]
  • [Cites] Soc Reprod Fertil Suppl. 2007;64:425-43 [17491163.001]
  • [Cites] Eur J Pediatr. 2007 Jul;166(7):671-8 [17103190.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3796-802 [17606710.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Aug;7(5):465-74 [17691906.001]
  • [Cites] Reprod Toxicol. 2007 Aug-Sep;24(2):240-52 [17706921.001]
  • [Cites] Rev Endocr Metab Disord. 2007 Jun;8(2):173-82 [17638084.001]
  • [Cites] Digestion. 2008;77 Suppl 1:2-12 [18204256.001]
  • [Cites] Fertil Steril. 2008 Feb;89(2 Suppl):e47-51 [18308062.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1485-93 [18392054.001]
  • [Cites] Lab Anim Sci. 1999 Oct;49(5):530-6 [10551455.001]
  • [CommentIn] Endocrinology. 2008 Dec;149(12):5919-21 [19022898.001]
  • (PMID = 18669593.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P50 ES015905; United States / NCI NIH HHS / CA / CA112532; United States / NIEHS NIH HHS / ES / R01 ES015584; United States / NIEHS NIH HHS / ES / ES015905; United States / NIEHS NIH HHS / ES / ES015584; United States / NCI NIH HHS / CA / R01 CA112532; United States / Intramural NIH HHS / / ; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NCI NIH HHS / CA / R01 CA015776; United States / NCI NIH HHS / CA / CA015776; United States / NHGRI NIH HHS / HG / R01 HG003749; United States / NHGRI NIH HHS / HG / HG003749; United States / NIEHS NIH HHS / ES / R21 ES013071; United States / NIEHS NIH HHS / ES / ES013071; United States / NIEHS NIH HHS / ES / ES006096
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HMGN Proteins; 731DCA35BT / Diethylstilbestrol; DH2M523P0H / Genistein
  • [Other-IDs] NLM/ PMC2613067
  •  go-up   go-down


Advertisement
4. Carlsson J, Helenius G, Karlsson M, Klinga-Levan K: Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma. Cancer Cell Int; 2010 Nov 24;10:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma.
  • In a previous microarray study performed by our group, Gpx3 was identified as a potential biomarker for rat endometrial adenocarcinoma (EAC), since the expression was highly downregulated in rat EAC tumors.
  • In addition we have examined the expression of GPX3 and MET in 30 human EACs of different FIGO grades and 20 benign endometrial tissues.
  • Preliminary results also suggest that the production of H2O2 is higher in rat endometrial tumors with down-regulated Gpx3 expression.
  • A likely consequence of loss of GPX3 protein function would be a higher amount of ROS in the cancer cell environment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Neonate. 1990;57(6):343-8 [2164849.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):85-94 [18175071.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):649-62 [15188130.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):794-8 [1846317.001]
  • [Cites] Z Versuchstierkd. 1987;30(5-6):209-16 [3445711.001]
  • [Cites] Cancer Cell Int. 2009;9:12 [19426485.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11715-20 [9751731.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1472-81 [17245700.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 [14685170.001]
  • [Cites] Oncogene. 1999 Apr 8;18(14):2343-50 [10327054.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2081-8 [17332337.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jun;127(2):118-27 [11425450.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4731-5 [8197126.001]
  • [Cites] J Natl Cancer Inst. 1987 Jun;78(6):1245-51 [3473261.001]
  • [Cites] Curr Probl Cancer. 1997 Mar-Apr;21(2):65-127 [9128804.001]
  • [Cites] Science. 1991 Feb 15;251(4995):802-4 [1846706.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8043-50 [17804715.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):1023-34 [11381087.001]
  • [Cites] Oncol Rep. 2008 Dec;20(6):1299-303 [19020706.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1282-93 [19195878.001]
  • [Cites] Cancer Detect Prev. 1987;10(3-4):237-46 [3568022.001]
  • [Cites] Int J Oncol. 2010 Feb;36(2):405-14 [20043075.001]
  • [Cites] Verh Dtsch Ges Pathol. 1997;81:228-32 [9474874.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):701-6 [9012848.001]
  • [Cites] Endocr Relat Cancer. 2003 Mar;10(1):23-42 [12653669.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4742-9 [16651427.001]
  • (PMID = 21106063.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3014921
  •  go-up   go-down


5. Bozas GT, Bamias A, Kastritis E, Rodolakis A, Vlahos G, Papadimitriou CA, Markaki S, Dimopoulos MA: Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus. Eur J Gynaecol Oncol; 2005;26(6):627-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus.
  • PURPOSE OF INVESTIGATION: Uterine papillary serous carcinoma (UPSC) and uterine clear cell carcinoma (UCCC) represent more aggressive tumors than the more common endometroid cancers, exhibiting a propensity for distant metastasis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Papillary / drug therapy. Endometrial Neoplasms / drug therapy

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398224.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Zhu LC, Yim J, Chiriboga L, Cassai ND, Sidhu GS, Moreira AL: DC-LAMP stains pulmonary adenocarcinoma with bronchiolar Clara cell differentiation. Hum Pathol; 2007 Feb;38(2):260-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DC-LAMP stains pulmonary adenocarcinoma with bronchiolar Clara cell differentiation.
  • DC-LAMP marks pulmonary adenocarcinomas that show Clara cell characteristics by electron microscopy.
  • DC-LAMP staining was lost in solid type adenocarcinomas but persisted in well-differentiated areas.
  • DC-LAMP and CC-10 reactivity was also observed in endometrial adenocarcinomas but not in other tumor types.
  • [MeSH-major] Adenocarcinoma / pathology. Bronchi / pathology. Lung Neoplasms / pathology. Lysosome-Associated Membrane Glycoproteins / analysis
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Female. Humans. Immunohistochemistry. Lung / chemistry. Lung / pathology. Lung / ultrastructure. Male. Microscopy, Electron. Middle Aged. Nuclear Proteins / analysis. Prognosis. Pulmonary Surfactants / analysis. Survival Rate. Transcription Factors / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056097.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Lysosome-Associated Membrane Glycoproteins; 0 / Nuclear Proteins; 0 / Pulmonary Surfactants; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


7. Hu K, Zhong G, He F: Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer; 2005 May-Jun;15(3):537-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma.
  • We assessed the expression of estrogen receptors (ER)alpha and ERbeta in 114 human endometrial hyperplasia and adenocarcinomas.
  • The aim of this study was to determine the expression of both ER isoforms in human endometrial tissue by immunohistochemistry.
  • In atypia hyperplasia and adenocarcinoma, both ERalpha and ERbeta were decreased significantly (P < 0.05).
  • Most endometrial adenocarcinomas expressed ERalpha, either alone or in combination with ERbeta, and the ERbeta/ERalpha ratio was decreased when compared to normal proliferation (P < 0.05).
  • Also, we found that the expression of ERalpha and ERbeta has no relationship with the status of lymph node of adenocarcinoma (P > 0.05).
  • Both ERalpha and ERbeta play an important role in endometrial hyperplasia and carcinomas, the levels of ERalpha and ERbeta appear be used as prognostic indicators.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Endometrial Hyperplasia / genetics. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Estrogen Receptor alpha / biosynthesis. Estrogen Receptor beta / biosynthesis. Gene Expression Profiling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882182.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Protein Isoforms
  •  go-up   go-down


8. Salakos N, Bakalianou K, Deligeoroglou E, Kondi-Pafiti A, Papadias K, Creatsas G: Endometrial carcinoma presenting as hematometra: clinicopathological study of a rare case and literature review. Eur J Gynaecol Oncol; 2007;28(3):239-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma presenting as hematometra: clinicopathological study of a rare case and literature review.
  • From her clinical history, a wide excision of the uterine cervix was reported due to a high-grade intraepithelial squamous neoplasia.
  • Laparotomy showed a greatly enlarged uterus and the histological exam revealed a hematometra with a superficial endometrioid adenocarcinoma of the uterine cavity.
  • A review of the literature revealed that hematometra in postmenopausal women should be investigated because it may harbor a cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Postmenopause
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Hematometra / diagnosis. Humans. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624098.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


9. Liao CL, Lee MY, Tyan YS, Kok LF, Wu TS, Koo CL, Wang PH, Chao KC, Han CP: Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. J Transl Med; 2009;7:37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study.
  • OBJECTIVE: Endocervical adenocarcinomas (ECA) and endometrial adenocarcinomas (EMA) are uterine malignancies that have differing biological behaviors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Endometrial Neoplasms / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Uterine Cervical Neoplasms / metabolism. Vimentin / metabolism
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry. Sensitivity and Specificity. Tissue Array Analysis


10. Srikantia N, B R, A G R, Kalyan SN: Endometrioid endometrial adenocarcinoma in a premenopausal woman with multiple organ metastases. Indian J Med Paediatr Oncol; 2009 Apr;30(2):80-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid endometrial adenocarcinoma in a premenopausal woman with multiple organ metastases.
  • Endometrial adenocarcinoma is the third common malignancy of the female genital tract occurring most often in the postmenopausal age group.
  • We present an unusual case of endometrial adenocarcinoma in a premenopausal woman with simultaneous metastases in brain, liver, skin and skeletal system, within one month of completion of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):530-3 [9190989.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):281-4 [12068176.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73 [15093913.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):524-8 [15099973.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Aug;4(4):679-89 [15270671.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):333-9 [15297170.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Sep;35(9):1488-94 [18799902.001]
  • [Cites] Anticancer Res. 2009 May;29(5):1715-20 [19443392.001]
  • (PMID = 20596308.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2885881
  • [Keywords] NOTNLM ; Adjuvant chemotherapy / endometrial carcinoma / multiple organ metastases
  •  go-up   go-down


11. Pozharisskiĭ KM, Samsonova EA, Ten VP, Maksimova NA, Urmancheeva AF: [Immunohistochemical profile of endometrioid adenocarcinoma of the uterus: ER, PR, HER-2, Ki-67 and their prognostic value]. Arkh Patol; 2005 Mar-Apr;67(2):13-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical profile of endometrioid adenocarcinoma of the uterus: ER, PR, HER-2, Ki-67 and their prognostic value].
  • 76 endometrioid adenocarcinomas of the uterine body were studied.
  • Expression of the above markers is of essential value together with metastatic involvement of regional lymph nodes, stage of the disease and pathogenetic variant for determining prognosis of carcinoma aggressiveness and disease outcome.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ki-67 Antigen / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Steroid / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938112.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Steroid; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


12. Hoekstra AV, Kim JJ, Keh P, Schink JC: Absence of progesterone receptors in a failed case of fertility-sparing treatment in early endometrial cancer: a case report. J Reprod Med; 2008 Nov;53(11):869-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of progesterone receptors in a failed case of fertility-sparing treatment in early endometrial cancer: a case report.
  • BACKGROUND: Fertility-sparing treatment may be offered as an alternative to standard surgical management of early-stage, well-differentiated endometrial cancer in young women.
  • CASE: We describe a 29-year-old woman who used oral contraceptive pills on a long-term basis in whom early-stage, well-differentiated endometrial cancer was diagnosed.
  • CONCLUSION: Combination oral contraceptive pills may stimulate clonal expansion of endometrial cells that lack PR, leading to endometrial adenocarcinoma unresponsive to progestin therapy.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MEGESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097521.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA127674-02; United States / NCI NIH HHS / CA / R21 CA127674; United States / NCI NIH HHS / CA / R21 CA127674-02
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Contraceptives, Oral, Hormonal; 0 / Progesterone Congeners; 0 / Receptors, Progesterone; EA6LD1M70M / Megestrol
  • [Other-IDs] NLM/ NIHMS282703; NLM/ PMC4780569
  •  go-up   go-down


13. Keese M, Back W, Dinter D, Gladisch R, Joos A, Palma P: Case report: late perianal mucinous adenocarcinoma after Crohn's disease proctectomy: an oncological rarity. World J Surg Oncol; 2005 Jun 29;3:42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: late perianal mucinous adenocarcinoma after Crohn's disease proctectomy: an oncological rarity.
  • BACKGROUND: As in ulcerative colitis, there is an increased incidence of colorectal carcinoma in Crohn's disease.
  • While carcinoma formation originating from ano-rectal fistulas is generally considered as a rare event there are different publications reporting on mucinous adenocarcinoma formation in association with a neovagina and rectovaginal fistulas.
  • To the best of our knowledge this is the first description of a perianal mucinous adenocarcinoma arising in a patient after Crohn's disease proctocolectomy.
  • CASE PRESENTATION: We report the case of a 50-year old female with a mucinous adenocarcinoma forming in the perineum eleven years after proctocolectomy for Crohn's disease.
  • The patient was readmitted with perineal pain, leucocytosis and a perineal mass highly suspicious of abscess formation in the MRI-Scan.
  • Histological examination revealed a mucinous adenocarcinoma.
  • Exenteration including vagina, uterus and ovaries together with the coccygeal-bone was performed.
  • CONCLUSION: Mucinous adenocarcinoma formation is a rare complication of Crohn's disease and so far unreported after proctocolectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1997 Apr;40(4):443-50 [9106694.001]
  • [Cites] J Surg Oncol. 2001 May;77(1):61-4 [11344485.001]
  • [Cites] Eur J Surg. 2000 Mar;166(3):218-22 [10755336.001]
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):272-5 [8314151.001]
  • [Cites] Cancer. 1976 Apr;37(4):1891-1900 [177180.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(2):CD000279 [15106148.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):266-8 [15047250.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:6-9 [12950414.001]
  • [Cites] Colorectal Dis. 2003 Sep;5(5):490-5 [12925087.001]
  • [Cites] Z Gastroenterol. 2002 Aug;40(8):569-76 [12297980.001]
  • [Cites] Am J Surg. 1980 Nov;140(5):642-4 [7435823.001]
  • [Cites] Am Surg. 1988 Nov;54(11):681-5 [2847606.001]
  • [Cites] Cancer. 1977 Mar;39(3):1295-9 [199346.001]
  • [Cites] Ann Surg. 1938 Nov;108(5):867-73 [17857277.001]
  • [Cites] Dis Colon Rectum. 1975 Apr;18(3):200-2 [1140047.001]
  • (PMID = 15987512.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1190221
  •  go-up   go-down


14. van de Poll-Franse LV, Mols F, Essink-Bot ML, Haartsen JE, Vingerhoets AJ, Lybeert ML, van den Berg HA, Coebergh JW: Impact of external beam adjuvant radiotherapy on health-related quality of life for long-term survivors of endometrial adenocarcinoma: a population-based study. Int J Radiat Oncol Biol Phys; 2007 Sep 1;69(1):125-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of external beam adjuvant radiotherapy on health-related quality of life for long-term survivors of endometrial adenocarcinoma: a population-based study.
  • PURPOSE: To compare the health-related quality of life (HRQOL) among 5-10-year survivors of Stage I-II endometrial (adeno-)carcinoma (EC) treated with surgery alone or surgery with external beam adjuvant radiotherapy (EBRT) and an age-matched norm population.
  • METHODS AND MATERIALS: A population-based, cross-sectional survey was conducted by the Eindhoven Cancer Registry.
  • Information from the questionnaires returned was linked to data from the Eindhoven Cancer Registry on patient, tumor, and treatment characteristics.
  • The analyses were restricted to women with Stage I-II disease at diagnosis, treated with either surgery alone or surgery with adjuvant EBRT, and without recurrent disease or new primary malignancies (n = 264).
  • The patients who had received adjuvant EBRT (n = 80) had had a significantly higher tumor stage and grade at diagnosis (p < 0.0001) and a longer mean time since diagnosis (p = 0.04).
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy. Health Status. Quality of Life

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17544600.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Neppe C, Land R, Obermair A: Wrigley forceps to deliver a bulky uterus following a total laparoscopic hysterectomy for endometrial cancer. Aust N Z J Obstet Gynaecol; 2005 Oct;45(5):444-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wrigley forceps to deliver a bulky uterus following a total laparoscopic hysterectomy for endometrial cancer.
  • Morcellation of the uterus is contraindicated in endometrial cancer and a uterine size of 11 weeks or larger has been considered a contraindication for total laparoscopic hysterectomy (TLH) in endometrial cancer.
  • We describe a new technique of removing a bulky uterus in a patient with endometrial cancer with the use of Wrigley forceps following a total laparoscopic hysterectomy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Hysterectomy / methods. Hysteroscopy / methods

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16171485.001).
  • [ISSN] 0004-8666
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


16. Zergeroğlu S, Ozdemir HB, Ozel M, Kuzey GM, Mollamahmutoğlu L: The prognostic importance of proliferative activity and oestrogen receptor expression in stage I endometrial carcinomas. J Obstet Gynaecol; 2006 Nov;26(8):798-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic importance of proliferative activity and oestrogen receptor expression in stage I endometrial carcinomas.
  • The purpose of this study was to evaluate the prognostic significance of steroid hormone receptor proliferation index in endometrial adenocarcinoma.
  • In this study, the correlation between oestrogen receptor expression, proliferation index and FIGO grade, age, myometrial invasion, tumour size and menopause status was evaluated in 40 patients with endometrial carcinoma.
  • Quantitative assessment of tumour proliferation and expression of oestrogen receptor were found to be important prognostic indicators in endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Receptors, Estrogen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17130035.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Estrogen
  •  go-up   go-down


17. McLucas B: Diagnosis, imaging and anatomical classification of uterine fibroids. Best Pract Res Clin Obstet Gynaecol; 2008 Aug;22(4):627-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis, imaging and anatomical classification of uterine fibroids.
  • Uterine leiomyomata, commonly referred to as fibroids, are often accompanied by symptoms common to many other pelvic conditions.
  • A confident diagnosis of myomata may be aided by several imaging modalities.
  • Myomata may be classified based upon position within the uterus, and may be further described by phase of degeneration.
  • With the increasing popularity of uterine-conserving therapy, accurate diagnosis of myomata becomes even more important.
  • [MeSH-major] Leiomyoma / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Diagnosis, Differential. Endometrial Neoplasms / diagnosis. Endometriosis / diagnosis. Female. Humans. Ovarian Neoplasms / diagnosis. Pelvic Neoplasms / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18328787.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 61
  •  go-up   go-down


18. Homesley HD: Present status and future direction of clinical trials in advanced endometrial carcinoma. J Gynecol Oncol; 2008 Sep;19(3):157-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Present status and future direction of clinical trials in advanced endometrial carcinoma.
  • Endometrial adenocarcinoma is staged surgically, and advanced endometrial carcinoma is considered to be FIGO stage III and IV.
  • The Gynecologic Oncology Group (GOG) has come a long way in developing new strategies in the management of advanced endometrial carcinoma.
  • Combining surgery, radiation, and chemotherapy, the 5-year survival has improved to between 40-60% in newly diagnosed advanced endometrial carcinoma.
  • Recent findings in GOG184 indicate that multiple risk factors noted at the time of surgical staging could lead to concurrent clinical trials that could be completed expeditiously rather than a subsequent ten year long phase III trial including all the various risk subgroups of patients.
  • This review is a focus on the accomplishments of the GOG in advanced endometrial carcinoma with an emphasis on future challenges.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1996 Dec;63(3):299-303 [8946862.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):1019-25 [1917597.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3902-8 [15459211.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):95-100 [15385116.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2159-66 [15169803.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):277-81 [12648575.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):349-54 [16213007.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • (PMID = 19471566.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676463
  • [Keywords] NOTNLM ; Chemotherapy / Clinical trial / Endometrial cancer / Radiotherapy / Therapy
  •  go-up   go-down


19. Cheng B, Wan X, Qian X, Lv W, Xie X: Results of conservative surgery for recurrent borderline ovarian tumors. Eur J Gynaecol Oncol; 2009;30(1):75-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The six patients (median age, 32 years) underwent fertility-sparing surgery, preserving the uterus and at least part of one ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Cystadenoma, Serous / surgery. Fertility. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317262.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. Soeda S, Nakamura N, Ozeki T, Nishiyama H, Hojo H, Yamada H, Abe M, Sato A: Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol; 2008 Apr;109(1):122-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma.
  • OBJECTIVE: This study was conducted to determine whether tumor-associated macrophages (TAMs) correlate with clinicopathological features in endometrioid adenocarcinoma.
  • METHODS: 76 cases of endometrioid adenocarcinoma treated initially by hysterectomy with pelvic lymphadenectomy were retrospectively retrieved, and their histological features were evaluated.
  • TAMs may play a significant role in the biology of tumor progression of endometrial adenocarcinoma, but do not appear to be independent prognostic indicators of patient's survival.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Macrophages / pathology. Myometrium / pathology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289648.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


21. Willis SF, Barton D, Ind TE: Laparoscopic hysterectomy with or without pelvic lymphadenectomy or sampling in a high-risk series of patients with endometrial cancer. Int Semin Surg Oncol; 2006;3:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic hysterectomy with or without pelvic lymphadenectomy or sampling in a high-risk series of patients with endometrial cancer.
  • BACKGROUND: The purpose of the study was to determine the outcome of all patients with endometrial adenocarcinoma cancer treated by laparoscopic hysterectomy at our institution, many of whom were high-risk for surgery.
  • METHODS: Data was collected by a retrospective search of the case notes and Electronic Patient Records of the thirty eight patients who underwent laparoscopic hysterectomy for endometrial cancer at our institutions.
  • Comorbidities were present in 76% (29 patients); 40% (15 patients) had a single comorbid condition, whilst 18% (7 patients) had two, and a further 18% (7 patients) had more than two.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2005 Sep-Oct;15(5):932-7 [16174248.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Oct;83 Suppl 1:79-118 [14763170.001]
  • [Cites] Arch Gynecol Obstet. 2004 Jul;270(1):25-30 [12728326.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(4):305-10 [12214729.001]
  • [Cites] Curr Opin Obstet Gynecol. 2005 Feb;17(1):77-82 [15711416.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):329-35 [10985889.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):239-44 [11161866.001]
  • [Cites] Cancer. 2001 Jan 15;91(2):378-87 [11180085.001]
  • [Cites] Gynecol Oncol. 1990 Nov;39(2):171-4 [2227591.001]
  • [Cites] Int J Gynecol Cancer. 2005 Sep-Oct;15(5):946-51 [16174250.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):789-93 [14984942.001]
  • [Cites] J Minim Invasive Gynecol. 2005 Mar-Apr;12(2):130-6 [15904616.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):4-9 [15790430.001]
  • [Cites] BJOG. 2005 Jan;112(1):115-7 [15663410.001]
  • (PMID = 16968556.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1586010
  •  go-up   go-down


22. Cannon GM, Geye H, Terakedis BE, Kushner DM, Connor JP, Hartenbach EM, Bradley KA: Outcomes following surgery and adjuvant radiation in stage II endometrial adenocarcinoma. Gynecol Oncol; 2009 May;113(2):176-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes following surgery and adjuvant radiation in stage II endometrial adenocarcinoma.
  • PURPOSE: To evaluate locoregional control, disease free survival, and overall survival in patients treated with surgery and adjuvant radiation for stage II adenocarcinoma of the endometrium.
  • MATERIALS AND METHODS: All patients receiving adjuvant radiation at the University of Wisconsin following surgery for FIGO stage II adenocarcinoma of the endometrium between January 1991 and December 2006 were retrospectively reviewed.
  • RESULTS: Between January 1991 and December 2006, 71 patients with FIGO stage II adenocarcinoma of the endometrium (23 stage IIA, 48 stage IIB) received adjuvant radiation at the University of Wisconsin.
  • DISCUSSION: Local recurrence rates remain low after surgery and adjuvant radiation therapy for stage II endometrial cancer using a combination of VB and EXT tailored to the surgical and pathologic features.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19217147.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA180799
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Koistinen H, Seppälä M, Knuutila S, Koistinen R: Extracellular matrix-induced changes in expression of cell cycle-related proteins and proteasome components in endometrial adenocarcinoma cells. Gynecol Oncol; 2006 Sep;102(3):546-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracellular matrix-induced changes in expression of cell cycle-related proteins and proteasome components in endometrial adenocarcinoma cells.
  • Whereas ECM has been shown to alter cellular morphology and reduce proliferation of HEC-1B endometrial adenocarcinoma cells, little is known about the underlying changes in gene expression.
  • METHODS: We studied by cDNA array the effects of ECM components, as present in Matrigel basement membrane cell culture matrix, on gene expression in HEC-1B endometrial adenocarcinoma cells in respect of the same cells cultured on conventional plastic surface.
  • RESULTS: As expected, several growth-promoting genes were downregulated, while many genes associated with growth restriction were upregulated in Matrigel-grown carcinoma cells.
  • The observed changes point to a less malignant phenotype of Matrigel-grown tumor cells, supported by reduced growth characteristics and morphology.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Cycle Proteins / metabolism. Endometrial Neoplasms / metabolism. Extracellular Matrix / physiology. Proteasome Endopeptidase Complex / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497364.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


24. Viswanathan AN, Feskanich D, Schernhammer ES, Hankinson SE: Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res; 2008 Apr 1;68(7):2507-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer.
  • To date, no prospective studies have explored the relationship between the use of aspirin, other nonsteroidal anti-inflammatory medications (NSAID), and acetaminophen and endometrial adenocarcinoma.
  • Of the 82,971 women enrolled in a prospective cohort study, 747 developed medical record-confirmed invasive endometrial cancer over a 24-year period.
  • Cox regression models calculated multivariate relative risks (MV RR), controlling for body mass index (BMI), postmenopausal hormone (PMH) use, and other endometrial cancer risk factors.
  • Currency, duration, and quantity of aspirin were not associated with endometrial cancer risk overall [current use: MV RR, 1.03; 95% confidence interval (CI) 0.83-1.27; >10 years of use: MV RR, 1.01; 95% CI, 0.78-1.30; and cumulative average >7 tablets per week: (MV RR, 1.10; 95% CI, 0.84-1.44)].
  • However, stratified analyses showed that a lower risk of endometrial cancer among obese (BMI, >or=30 kg/m(2)) women was seen with current aspirin use (MV RR, 0.66; 95% CI, 0.46-0.95).
  • The use of other NSAIDs or acetaminophen was not associated with endometrial cancer.
  • Our data suggest that use of aspirin or other NSAIDs does not play an important role in endometrial cancer risk overall.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 2000 Jan;182(1 Pt 1):23-9 [10649152.001]
  • [Cites] Int J Gynecol Cancer. 2007 Mar-Apr;17(2):447-54 [17316360.001]
  • [Cites] Epidemiology. 2001 Jan;12(1):88-93 [11138826.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Obstet Gynecol. 2001 Mar;97(3):423-7 [11239649.001]
  • [Cites] J Exp Med. 2001 Mar 19;193(6):F23-6 [11257144.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1023-31 [11592775.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26208-16 [12006564.001]
  • [Cites] Cancer. 2002 Aug 15;95(4):801-7 [12209724.001]
  • [Cites] J Reprod Immunol. 2002 Oct-Nov;57(1-2):81-93 [12385835.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1531-43 [12496040.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1586-91 [12496048.001]
  • [Cites] Ann Med. 2002;34(6):428-33 [12523498.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6096-101 [14522941.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):501-7 [14623550.001]
  • [Cites] J Natl Cancer Inst. 2004 Jan 7;96(1):22-8 [14709735.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 7;96(7):524-8 [15069114.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):525-9 [15226764.001]
  • [Cites] Am J Epidemiol. 1982 Aug;116(2):333-42 [7114042.001]
  • [Cites] Biol Rev Camb Philos Soc. 1986 Nov;61(4):313-28 [3542071.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):319-25 [3605058.001]
  • [Cites] Contraception. 1987 Jul;36(1):23-35 [3311624.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4399-404 [3390835.001]
  • [Cites] Int J Cancer. 1989 May 15;43(5):795-9 [2714884.001]
  • [Cites] Epidemiology. 1990 Nov;1(6):466-73 [2090285.001]
  • [Cites] Int J Cancer. 1991 Aug 19;49(1):38-43 [1874568.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):567-71 [1537622.001]
  • [Cites] J Natl Cancer Inst. 1993 Aug 4;85(15):1220-4 [8331682.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):609-14 [7637720.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Am J Obstet Gynecol. 2003 May;188(5):1174-6 [12748469.001]
  • [Cites] Prog Exp Tumor Res. 2003;37:1-24 [12795046.001]
  • [Cites] Endocrinology. 1996 Dec;137(12):5739-42 [8940410.001]
  • [Cites] J Womens Health. 1997 Feb;6(1):49-62 [9065374.001]
  • [Cites] Fertil Steril. 1998 Aug;70(2):371-3 [9696240.001]
  • [Cites] Lancet. 1999 May 29;353(9167):1824-8 [10359406.001]
  • [Cites] Int J Cancer. 1999 Jul 2;82(1):38-42 [10360818.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1131-7 [10393721.001]
  • [Cites] Contraception. 2004 Dec;70(6):451-62 [15541406.001]
  • [Cites] Cancer Sci. 2004 Nov;95(11):901-7 [15546508.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Feb;72(2):85-7 [15626590.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):996-1001 [15645490.001]
  • [Cites] Am J Obstet Gynecol. 2005 Apr;192(4):1262-71; discussion 1271-3 [15846217.001]
  • [Cites] JAMA. 2005 Jul 6;294(1):47-55 [15998890.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2840-7 [16364998.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2923-8 [16365011.001]
  • [Cites] Ann Intern Med. 2007 Mar 6;146(5):365-75 [17339622.001]
  • [Cites] J Clin Epidemiol. 2000 Apr;53(4):385-91 [10785569.001]
  • (PMID = 18381460.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / CA117979-04; United States / NCI NIH HHS / CA / K07 CA117979-04; United States / NCI NIH HHS / CA / CA87969; United States / NCI NIH HHS / CA / K07 CA117979-01; United States / NCI NIH HHS / CA / CA117979-02; United States / NCI NIH HHS / CA / CA117979-01; United States / NCI NIH HHS / CA / K07 CA117979; United States / NCI NIH HHS / CA / K07 CA117979-02; United States / NCI NIH HHS / CA / K07 CA117979-03; United States / NCI NIH HHS / CA / CA117979-03; United States / NCI NIH HHS / CA / 5K07 CA117979-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 362O9ITL9D / Acetaminophen; R16CO5Y76E / Aspirin
  • [Other-IDs] NLM/ NIHMS191688; NLM/ PMC2857531
  •  go-up   go-down


25. Wang C, Norton JT, Ghosh S, Kim J, Fushimi K, Wu JY, Stack MS, Huang S: Polypyrimidine tract-binding protein (PTB) differentially affects malignancy in a cell line-dependent manner. J Biol Chem; 2008 Jul 18;283(29):20277-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RNA processing is altered during malignant transformation, and expression of the polypyrimidine tract-binding protein (PTB) is often increased in cancer cells.
  • Although some data support that PTB promotes cancer, the functional contribution of PTB to the malignant phenotype remains to be clarified.
  • Here we report that although PTB levels are generally increased in cancer cell lines from multiple origins and in endometrial adenocarcinoma tumors, there appears to be no correlation between PTB levels and disease severity or metastatic capacity.
  • Reduction of PTB inhibits the invasive behavior of two cancer cell lines in Matrigel invasion assays but enhances the invasive behavior of another.
  • These data demonstrate that PTB is not oncogenic and can either promote or antagonize a malignant trait dependent upon the specific intra-cellular environment.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):800-6 [16282332.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 May;6(5):386-98 [15956978.001]
  • [Cites] Bioessays. 2006 Apr;28(4):378-86 [16547952.001]
  • [Cites] Nat Struct Mol Biol. 2006 Sep;13(9):839-48 [16936729.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(23):8755-69 [16982681.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):4961-8 [17310993.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1221-4 [10728679.001]
  • [Cites] J Biol Chem. 2000 Aug 4;275(31):23869-76 [10791952.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):938-43 [11158574.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3281-8 [11313454.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):8535-43 [11116151.001]
  • [Cites] RNA. 2001 Jun;7(6):819-32 [11421360.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(23):8238-46 [11710333.001]
  • [Cites] Mol Biol Cell. 2001 Dec;12(12):3808-20 [11739782.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):943-9 [12419237.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2524-33 [12467066.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 15;31(2):639-46 [12527772.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):419-37 [12600935.001]
  • [Cites] RNA. 2003 Apr;9(4):443-56 [12649496.001]
  • [Cites] Mol Biol Cell. 2003 Jun;14(6):2425-35 [12808040.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8776-81 [12851456.001]
  • [Cites] Annu Rev Biochem. 2003;72:291-336 [12626338.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6154-7 [14559795.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):9-14 [14769134.001]
  • [Cites] Mol Cell Biol. 2004 May;24(10):4174-83 [15121839.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4652-60 [15269137.001]
  • [Cites] Cancer Res. 1984 Aug;44(8):3522-9 [6744277.001]
  • [Cites] Biochemistry. 1990 May 22;29(20):4966-70 [2114170.001]
  • [Cites] Cell. 1991 Apr 5;65(1):13-24 [1707342.001]
  • [Cites] Genes Dev. 1991 Jul;5(7):1224-36 [1906035.001]
  • [Cites] Genes Dev. 1991 Jul;5(7):1237-51 [1906036.001]
  • [Cites] Nucleic Acids Res. 1992 Jul 25;20(14):3671-8 [1641332.001]
  • [Cites] Mol Cell Biol. 1993 May;13(5):2993-3001 [8474457.001]
  • [Cites] J Virol. 1994 Feb;68(2):941-50 [8289396.001]
  • [Cites] Cell. 1994 Sep 9;78(5):739-50 [8087842.001]
  • [Cites] Virology. 1995 Dec 20;214(2):660-3 [8553572.001]
  • [Cites] RNA. 1995 Nov;1(9):924-38 [8548657.001]
  • [Cites] Genes Dev. 1996 Jan 15;10(2):208-19 [8566754.001]
  • [Cites] Mol Cell Biol. 1996 Oct;16(10):5400-8 [8816452.001]
  • [Cites] J Cell Biol. 1997 Jun 2;137(5):965-74 [9166399.001]
  • [Cites] RNA. 1997 Jul;3(7):764-78 [9214659.001]
  • [Cites] Biochemistry. 1997 Sep 30;36(39):11881-90 [9305981.001]
  • [Cites] Curr Biol. 1997 Nov 1;7(11):R705-8 [9382788.001]
  • [Cites] Biochem J. 1998 Apr 1;331 ( Pt 1):169-75 [9512476.001]
  • [Cites] Clin Cancer Res. 1996 Sep;2(9):1627-36 [9816342.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):78-85 [9858533.001]
  • [Cites] Electrophoresis. 1999 Apr-May;20(4-5):1082-6 [10344288.001]
  • [Cites] Gene. 2005 Jan 3;344:1-20 [15656968.001]
  • [Cites] J Cell Biochem. 2005 May 15;95(2):217-25 [15770648.001]
  • [Cites] Thromb Haemost. 2005 Apr;93(4):676-81 [15841311.001]
  • [Cites] Nat Methods. 2004 Dec;1(3):233-9 [15782199.001]
  • [Cites] Trends Biochem Sci. 2006 Feb;31(2):73-6 [16403634.001]
  • (PMID = 18499661.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM 078555-01; United States / NIGMS NIH HHS / GM / GM 070967; United States / NCI NIH HHS / CA / R21 CA127674-01A2; United States / NCI NIH HHS / CA / CA127674-01A2; United States / NCI NIH HHS / CA / R21 CA127674; United States / NCI NIH HHS / CA / CA 097761
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / RNA, Small Interfering; 139076-35-0 / Polypyrimidine Tract-Binding Protein; EC 3.4.22.- / Caspase 2
  • [Other-IDs] NLM/ PMC2459264
  •  go-up   go-down


26. Erkanli S, Bolat F, Kayaselcuk F, Demirhan B, Kuscu E: COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol Oncol; 2007 Feb;104(2):320-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma.
  • OBJECTIVES: To investigate the expressions of survivin and Cyclooxygenase-2 (COX-2), and their possible correlations in the development of endometrial adenocarcinoma (EC).
  • METHODS: Archived tissue samples of 50 EC, 30 endometrial hyperplasia and 20 proliferative endometrium were selected and immunohistochemically analyzed for survivin and COX-2 expression.
  • RESULTS: Both survivin and COX-2 were overexpressed in hyperplasia and endometrial adenocarcinoma cases compared to proliferative endometrium, which was statistically significant (p=0.01, p=0.02, respectively).
  • Neither survivin nor COX-2 expression was correlated with classical prognostic factors of endometrial carcinoma such as myometrial invasion, grade or lymph node metastasis (p>0.05).
  • Molecular basis of such a relationship should be further investigated in endometrial carcinogenesis.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Endometrioid / metabolism. Cyclooxygenase 2 / biosynthesis. Endometrial Neoplasms / metabolism. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Endometrial Hyperplasia / enzymology. Endometrial Hyperplasia / metabolism. Endometrial Hyperplasia / pathology. Female. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030351.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


27. Roncati L, Barbolini G, Ghirardini G, Rivasi F: Mature solid teratoma of the fallopian tube mimicking metastasis of endometrial adenocarcinoma: a case report. Int J Surg Pathol; 2010 Dec;18(6):561-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature solid teratoma of the fallopian tube mimicking metastasis of endometrial adenocarcinoma: a case report.
  • This mass was noted on CT scan and considered metastatic in nature since following a bioptical diagnosis of endometrial adenocarcinoma.
  • Hysterectomy and bilateral salpingectomy and ovariectomy were performed and a second minor mature solid teratoma was discovered inside the right ovary.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Teratoma / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282291.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Horn LC, Hänel C, Bartholdt E, Dietel J: Mixed serous carcinoma of the endometrium with trophoblastic differentiation: analysis of the p53 tumor suppressor gene suggests stem cell origin. Ann Diagn Pathol; 2008 Feb;12(1):1-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed serous carcinoma of the endometrium with trophoblastic differentiation: analysis of the p53 tumor suppressor gene suggests stem cell origin.
  • The pathogenesis of mixed endometrial adenocarcinoma with trophoblastic differentiation is quite unclear at times.
  • The present study examines a serous carcinoma with choriocarcinomatous differentiation. p53 staining was seen in the serous component and the cytotrophoblastic cells of the choriocarcinomatous component, but not in the syncytiotrophoblastic cells. p53 mutational analysis showed a heterozygotic mutation at exon 8 for the choriocarcinomatous component and a homozygote deletion at exon 7 for the serous component.
  • [MeSH-major] Adenocarcinoma / genetics. Choriocarcinoma / genetics. Endometrial Neoplasms / genetics. Neoplasms, Multiple Primary / genetics. Trophoblastic Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164407.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


29. Zhang Y, Zhang Y, Lin QH: [Progesterone-modulated proteins in human endometrial cancer cell line Ishikawa]. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug;26(8):1110-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progesterone-modulated proteins in human endometrial cancer cell line Ishikawa].
  • OBJECTIVE: To identify proteins associated with growth inhibitory effects of progesterone in Ishikawa endometrial adenocarcinoma cell line (Ishikawa).
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Line, Tumor. Down-Regulation / drug effects. Electrophoresis, Gel, Two-Dimensional. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Female. Humans. Mass Spectrometry. Megestrol Acetate / pharmacology. Up-Regulation / drug effects

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939895.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proteins; 0 / Proteome; 4G7DS2Q64Y / Progesterone; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


30. Graziani G, Tentori L, Muzi A, Vergati M, Tringali G, Pozzoli G, Navarra P: Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol; 2007 Jan 29;264(1-2):44-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype.
  • It has been previously shown that corticotropin-releasing hormone (CRH) exerts antiproliferative activity on an estrogen-dependent tumor cell line, i.e. human endometrial adenocarcinoma Ishikawa (IK) cells.
  • Here we have investigated the effects of CRH on another estrogen-dependent tumor cell line, human breast cancer MCF7 cells.
  • We have also investigated the putative source of CRH acting on breast cancer cells; we found that MCF7 cells express CRH mRNA under basal conditions and secrete sizable amounts of immunoreactive CRH, which leads to postulate the existence of paracrine-autocrine inhibitory mechanism operated by CRH in breast cancer cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hormones.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097220.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CRF receptor type 1; 0 / Hormones; 0 / Pyrimidines; 0 / Pyrroles; 0 / Receptors, Corticotropin-Releasing Hormone; 0 / antalarmin; 4TI98Z838E / Estradiol; 9015-71-8 / Corticotropin-Releasing Hormone
  •  go-up   go-down


31. Trimble EL, Harlan LC, Clegg LX, Stevens JL: Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States. Gynecol Oncol; 2005 Mar;96(3):741-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States.
  • INTRODUCTION: Non-Hispanic black women are less often diagnosed with endometrial cancer than are non-Hispanic white women, but are more likely to die of their disease.
  • METHODS: The Surveillance, Epidemiology, and End-Results Program data were used to sample women newly diagnosed in 1998 with cancer of the corpus uteri.
  • A total of 711 women with no previous diagnosis of cancer were selected.
  • CONCLUSIONS: Our study did not show any difference in recommended therapy for women with uterine adenocarcinoma among NH black women, NH white women, and Hispanic women.
  • We must look for other factors, therefore, to explain the disparities in cancer outcome observed among NH black women with endometrial cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721420.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Ditto A, Martinelli F, Carcangiu ML, Hanozet F, Solima E, Barisella M, Cerrotta A, Raspagliesi F: Incidental diagnosis of primary vaginal adenocarcinoma of intestinal type: a case report and review of the literature. Int J Gynecol Pathol; 2007 Oct;26(4):490-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental diagnosis of primary vaginal adenocarcinoma of intestinal type: a case report and review of the literature.
  • Primary vaginal adenocarcinoma of intestinal type is a rare malignant gynecologic disease.
  • A 53-year-old woman was admitted to our institution with a diagnosis of endometrial adenocarcinoma.
  • The patient underwent surgery for endometrial cancer and wedge resection of the vaginal lesion.
  • The diagnosis of primary vaginal adenocarcinoma of intestinal type was obtained after standard and immunohistochemical analyses of the specimen.
  • No endometrial cancer was detected in the specimen.
  • Extensive radiological investigations and careful immunohistochemical analysis of the specimen are needed for a correct diagnosis of vaginal adenocarcinoma of intestinal type.
  • [MeSH-major] Adenocarcinoma / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Endometrial Neoplasms / pathology. Female. Gynecologic Surgical Procedures. Humans. Immunohistochemistry. Incidental Findings. Intestinal Neoplasms / pathology. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Radiotherapy

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885503.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Gien LT, Barbera L, Kupets R, Saskin R, Paszat L: Utilization of preoperative imaging in uterine cancer patients. Gynecol Oncol; 2009 Nov;115(2):226-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utilization of preoperative imaging in uterine cancer patients.
  • This study evaluates patterns of preoperative ultrasound, CT and MRI use among uterine cancer patients in Ontario.
  • METHODS: This population-based study identified women diagnosed with uterine malignancy from 1995-2005 in the Ontario Cancer Registry.
  • Record linkages were made to other healthcare databases to characterize residence, socioeconomic status, comorbidities, and timing of investigations surrounding diagnosis.
  • RESULTS: We identified 12,522 women who received surgery for uterine adenocarcinoma or sarcoma, of which 9145 (73%) had a preoperative ultrasound, and 1148 (9.2%) had a preoperative CT and/or MRI.
  • Higher rates of CT/MRI use were associated with non-endometrioid high-risk histology (33.5% vs 14.6%, p<0.0001).
  • Time from diagnosis to surgery was 2 weeks longer if a preoperative CT/MRI was done.
  • CONCLUSIONS: The rate of preoperative CT and MRI use in patients with uterine cancer has increased twice as much as the reported rate in cancer patients overall.
  • Given the questionable utility of preoperative CT/MRI in this disease, guidelines should be developed for use of these imaging tests in uterine cancer, especially when use is associated with a delay in surgery.
  • [MeSH-major] Adenocarcinoma / diagnosis. Sarcoma / diagnosis. Uterine Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19683807.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Sales KJ, Grant V, Cook IH, Maldonado-Pérez D, Anderson RA, Williams AR, Jabbour HN: Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1. Am J Pathol; 2010 Jan;176(1):435-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1.
  • This study investigated the expression of IL-11 and role of prostaglandin F(2alpha)-F-prostanoid receptor (FP receptor) signaling in the modulation of IL-11 expression in endometrial adenocarcinoma cells.
  • IL-11 and regulator of calcineurin 1 isoform 4 (RCAN1-4) mRNA and protein expression were determined by real-time RT-PCR and/or enzyme-linked immunosorbent assay/Western blot analysis using Ishikawa endometrial adenocarcinoma cells stably expressing the FP receptor (FPS cells) and endometrial adenocarcinoma explants.
  • IL-11 mRNA expression was significantly elevated in endometrial adenocarcinoma samples compared with normal endometrium and increased with tumor grade.
  • IL-11 protein expression localized with FP receptor, IL-11Ralpha, and GP130 in the neoplastic glandular epithelium of endometrial adenocarcinomas.
  • Indeed, RCAN1-4 expression was significantly elevated in well-differentiated endometrial adenocarcinoma compared with normal endometrium and was found to decrease with tumor grade and negatively regulate IL-11 expression in vitro.
  • This study has highlighted a new mechanism regulating IL-11 expression in endometrial adenocarcinoma cells by the FP receptor via the calcium-calcineurin-nuclear factor of activated T cells pathway.
  • [MeSH-major] Calcineurin / metabolism. Calcium / metabolism. Endometrial Neoplasms / genetics. Interleukin-11 / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Muscle Proteins / metabolism. NFATC Transcription Factors / metabolism. Receptors, Prostaglandin / metabolism
  • [MeSH-minor] Aged. Cell Differentiation. Cell Proliferation. Cytokine Receptor gp130 / genetics. Cytokine Receptor gp130 / metabolism. Endometrium / metabolism. Endometrium / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Models, Biological. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Interleukin-11 / genetics. Receptors, Interleukin-11 / metabolism

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1681-90 [10861295.001]
  • [Cites] Biochim Biophys Acta. 2009 Jul;1793(7):1315-24 [19348862.001]
  • [Cites] Mol Hum Reprod. 2000 Oct;6(10):907-14 [11006319.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):25-32 [11141475.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):357-64 [11162945.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):121-7 [11161848.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1023-31 [11592775.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38787-94 [11483593.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Jul;302(1):219-24 [12065720.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Oct 15;138(2):165-8 [12505265.001]
  • [Cites] Mol Hum Reprod. 2003 Feb;9(2):75-80 [12569176.001]
  • [Cites] Eur J Pharmacol. 2003 Mar 28;465(1-2):39-41 [12650831.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Apr;88(4):1825-32 [12679480.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):986-93 [14764825.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):1-16 [2026352.001]
  • [Cites] Nucleic Acids Res. 1992 May 11;20(9):2233-9 [1317548.001]
  • [Cites] Cancer Surv. 1994;19-20:287-307 [7895220.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3115-20 [8610178.001]
  • [Cites] Biochem J. 1998 Sep 1;334 ( Pt 2):297-314 [9716487.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50537-54 [15448146.001]
  • [Cites] J Reprod Immunol. 2004 Dec;64(1-2):145-55 [15596233.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7707-16 [16140938.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13075-80 [16131541.001]
  • [Cites] Endocrinology. 2005 Nov;146(11):4657-64 [16081631.001]
  • [Cites] Hum Reprod Update. 2005 Nov-Dec;11(6):613-30 [16006437.001]
  • [Cites] Cell Tissue Res. 2005 Oct;322(1):53-61 [15947972.001]
  • [Cites] J Reprod Immunol. 2006 Feb;69(1):53-64 [16310857.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):317-21 [16482637.001]
  • [Cites] J Surg Res. 2006 Apr;131(2):267-75 [16457848.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):941-51 [16567391.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):802-8 [16614887.001]
  • [Cites] Int J Oncol. 2006 Oct;29(4):869-76 [16964382.001]
  • [Cites] Mol Cancer Res. 2006 Nov;4(11):811-20 [17114339.001]
  • [Cites] Int J Mol Med. 2007 Feb;19(2):273-8 [17203201.001]
  • [Cites] Int J Oncol. 2007 Apr;30(4):825-33 [17332920.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3635-44 [17478553.001]
  • [Cites] FASEB J. 2007 Oct;21(12):3023-8 [17595344.001]
  • [Cites] Endocrinology. 2007 Nov;148(11):5566-72 [17702845.001]
  • [Cites] Mol Cell Endocrinol. 2008 Mar 26;285(1-2):51-61 [18316157.001]
  • [Cites] Oncogene. 2008 Apr 10;27(17):2466-77 [17968320.001]
  • [Cites] J Biol Chem. 2000 Sep 22;275(38):29907-14 [10893233.001]
  • (PMID = 20008143.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127684438
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-11; 0 / Intracellular Signaling Peptides and Proteins; 0 / Muscle Proteins; 0 / NFATC Transcription Factors; 0 / RCAN1 protein, human; 0 / RNA, Messenger; 0 / Receptors, Interleukin-11; 0 / Receptors, Prostaglandin; 0 / prostaglandin F2alpha receptor; 133483-10-0 / Cytokine Receptor gp130; EC 3.1.3.16 / Calcineurin; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2797902
  •  go-up   go-down


35. Buchynska LG, Nesina IP, Kashuba EV: Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia. Exp Oncol; 2007 Dec;29(4):287-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia.
  • AIM: To study the expression of p53, MDM2, and p14 ARF in the highly, moderately and low differentiated endometrial adenocarcinomas, compared to hyperplasia.
  • MATERIAL AND METHODS: Surgical material and the scrapes of endometrial cancer, glandular and atypical hyperplasia patients.
  • RESULTS: High p53 expression level is accompanied by decreased level of MDM2 expression in endometrial cancers.
  • On contrary, in endometrial hyperplasia, there was clear connection between the expression levels of p53 and MDM2.
  • We hypothesize that the high p53 and low MDM2 levels in endometrial cancers could arise due to the inhibition of transcriptional activity of p53 by its binding to estrogen receptors.
  • CONCLUSION: High p53 expression level with low MDM2 and p14 ARF levels may be the characteristic features of low differentiated endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Proto-Oncogene Proteins c-mdm2 / biosynthesis. Tumor Suppressor Protein p14ARF / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199985.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


36. Siami K, McCluggage WG, Ordonez NG, Euscher ED, Malpica A, Sneige N, Silva EG, Deavers MT: Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. Am J Surg Pathol; 2007 Nov;31(11):1759-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas.
  • Thyroid transcription factor-1 (TTF-1) is widely used in the diagnosis of lung and thyroid carcinomas.
  • Although there have been reports of TTF-1 immunoreactivity in tumors other than those originating in the lung or thyroid, endocervical and endometrial adenocarcinomas have not been studied in large numbers.
  • Twenty-eight endocervical (9 well, 12 moderately, and 7 poorly differentiated), 32 endometrioid endometrial adenocarcinomas (11 grade I, 8 grade II, and 13 grade III), and 13 uterine serous carcinomas were retrieved and stained with TTF-1.
  • TTF-1 expression was seen in 1 of 28 (4%) of the endocervical adenocarcinomas and this was 4+ in distribution.
  • The positive endocervical carcinoma was poorly differentiated.
  • TTF-1 expression was present in 6 of 32 (19%) of the endometrioid adenocarcinomas (1 grade I, 2 grade II, and 3 grade III) and varied from 1+ to 4+ in distribution.
  • Only 2 of 32 (6%) of the endometrioid adenocarcinomas stained diffusely (4+).
  • There was no apparent correlation between the degree of differentiation and TTF-1 positivity in the adenocarcinomas.
  • Three of 13 (23%) serous carcinomas were also positive (1 case 5+ and 2 cases 1+).
  • Although TTF-1 is generally considered to be a relatively specific marker for lung and thyroid neoplasms, the occasional expression of endometrial and endocervical carcinomas should be kept in mind when evaluating neoplasms of uncertain origin.
  • It should also be taken into consideration in the evaluation of adenocarcinomas involving the lung in patients with a history of a gynecologic malignancy.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Cystadenocarcinoma, Serous / chemistry. Endometrial Neoplasms / chemistry. Nuclear Proteins / analysis. Transcription Factors / analysis. Uterine Cervical Neoplasms / chemistry. Uterine Neoplasms / chemistry


37. Preissel AK, Brugger N, Stassen T, Nuss K: [Treatment of a uterine adenocarcinoma in a miniature pig by ovariohysterectomy]. Schweiz Arch Tierheilkd; 2009 May;151(5):229-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of a uterine adenocarcinoma in a miniature pig by ovariohysterectomy].
  • A ventral midline approach was chosen to remove the ovaries and uterus, which contained brown fluid and multifocal masses in the uterine wall.
  • Histological examination of the uterine masses revealed leiomyoma, cystic hyperplasia and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / veterinary. Hysterectomy / veterinary. Ovariectomy / veterinary. Swine Diseases / surgery. Swine, Miniature. Uterine Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19421955.001).
  • [ISSN] 0036-7281
  • [Journal-full-title] Schweizer Archiv für Tierheilkunde
  • [ISO-abbreviation] Schweiz. Arch. Tierheilkd.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


38. Juretzka MM, O'Hanlan KA, Katz SL, El-Danasouri I, Westphal LM: Embryo cryopreservation after diagnosis of stage IIB endometrial cancer and subsequent pregnancy in a gestational carrier. Fertil Steril; 2005 Apr;83(4):1041
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryo cryopreservation after diagnosis of stage IIB endometrial cancer and subsequent pregnancy in a gestational carrier.
  • OBJECTIVE: To describe a case of embryo cryopreservation before hysterectomy and bilateral salpingo-oophorectomy for endometrial cancer.
  • PATIENT(S): An infertile woman with endometrial biopsy demonstrating grade II/III moderately differentiated endometrial adenocarcinoma.
  • INTERVENTION(S): A Progestasert intrauterine device (IUD) was inserted into the uterine cavity to potentially reduce tumor proliferation during the stimulation cycle followed by oocyte retrieval and cryopreservation of 14 embryos.
  • CONCLUSION(S): Embryo cryopreservation and use of a gestational carrier may offer a fertility option for patients with endometrial malignancies without substantially delaying treatment.
  • [MeSH-major] Adenocarcinoma / surgery. Cryopreservation / methods. Embryo Transfer. Embryo, Mammalian / physiology. Endometrial Neoplasms / surgery. Infertility, Female / therapy. Pregnancy Outcome. Surrogate Mothers


39. Oshiro H, Miyagi Y, Kawaguchi Y, Rino Y, Arai H, Asai-Sato M, Nakayama H, Yamanaka S, Inayama Y, Fukushima N: Endometrial adenocarcinoma without myometrial invasion metastasizing to the pancreas and masquerading as primary pancreatic neoplasm. Pathol Int; 2008 Jul;58(7):456-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma without myometrial invasion metastasizing to the pancreas and masquerading as primary pancreatic neoplasm.
  • Reported herein is a case of endometrial adenocarcinoma without myometrial invasion that metastasized to the pancreas in a 69-year-old Japanese woman who had a history of hysterectomy.
  • Excised in distal pancreatectomy, the tumor was diagnosed as a pancreatic primary, an invasive papillary adenocarcinoma at first, but both the endometrial tumor and the pancreatic tumor demonstrated similar morphology and immunohistochemistry.
  • Furthermore, the identical nucleotide mutation of TP53 gene was observed from both the endometrial and pancreatic tumors.
  • The pancreatic tumor was therefore confirmed to be a metastasis from the primary endometrial adenocarcinoma.
  • Metastasis to the pancreas from endometrial carcinoma is extremely rare but must be considered even if the previous cancer was treated at an early stage.
  • Histopathological comparison study and genetic analysis are important for the correct diagnosis of metastasis.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Aged. Base Sequence. Diagnosis, Differential. Female. Genes, p53. Humans. Hysterectomy. Immunohistochemistry. Molecular Sequence Data. Mutation

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18577117.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


40. Silva EG, Deavers MT, Bodurka DC, Malpica A: Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol; 2006 Jan;25(1):52-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?
  • Low-grade endometrioid carcinomas, either of the endometrium or the ovaries, usually have an excellent prognosis.
  • The association of this type of tumor with undifferentiated carcinoma is rare.
  • The endometrioid carcinoma involved the endometrium in 14 cases, the endometrium and 1 or both ovaries in 9 cases, and the ovaries in 2 cases.
  • Undifferentiated carcinoma associated with low-grade endometrioid carcinoma was found at presentation in 19 grade 1 or 2 endometrioid carcinomas: 15 in the endometrium and 5 in the ovary.
  • In one of these cases, undifferentiated carcinoma was found in the endometrium and the ovary.
  • Undifferentiated carcinoma was found after resection of low-grade endometrioid carcinoma in six cases, involving the retroperitoneum, pelvis, vagina, or liver.
  • The undifferentiated carcinoma was composed exclusively of diffuse sheets and solid nests of epithelial cells in l0 cases.
  • In four cases, the diagnosis was made recently, with short follow-ups of 3 and 4 months.
  • Foci of undifferentiated carcinoma may be confused with solid endometrioid adenocarcinoma erroneously leading to the diagnosis of a grade 3 or a significantly less aggressive grade 2 endometrioid carcinoma.
  • The recognition of undifferentiated carcinoma in an otherwise low-grade endometrioid adenocarcinoma is extremely important because it indicates aggressive behavior.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cell Transformation, Neoplastic. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Pathol. 2006 Jul;25(3):304
  • (PMID = 16306785.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


41. Risse EK, Ouwerkerk-Noordam E, Meijer-Marres EM, Boon ME: Exploiting the residual of cervical thin layer brush samples through cytohistology in cases with invasive carcinoma with application of antibodies. Acta Cytol; 2010 Mar-Apr;54(2):175-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploiting the residual of cervical thin layer brush samples through cytohistology in cases with invasive carcinoma with application of antibodies.
  • OBJECTIVE: To exploit cervical thin layer brush samples through cytohistology in cases with invasive carcinoma with application of antibodies.
  • STUDY DESIGN: Fourteen cases from women with carcinoma diagnosed in 2006 were selected out of 29 invasive carcinomas.
  • Eight women had squamous cell carcinoma, 4 endocervical adenocarcinoma, 1 endometrial adenocarcinoma and 1 ovarian adenocarcinoma.
  • These were stained with the Papanicolaou method and for the biomarkers Ki-67 and p16 and, if desired, for differentiation markers, including carcinoembryonic antigen, vimentin, cytokeratin 7 and cytokeratin 20 to establish the immunoprofile of the carcinoma.
  • RESULTS: The morphologic details in the cancer nuclei in the paraffin sections were excellent, while in all cases the thin layer cytology slide contained thick epithelial fragments with blurred nuclei.
  • In 5 of the 6 adenocarcinomas, the glandular architecture diagnostic of adenocarcinoma was visible in the cytohistology, which was highlighted in the biomarker stainings, particularly so in the Ki-67 sections.
  • With the exception of endometrial adenocarcinoma, all p16(INK4a) stainings were positive, as they were in the ovarian adenocarcinoma case.
  • CONCLUSION: Cytohistology is an adjunct to routine cervical cytologic examination of thin layer samples, allowing an unequivocal and refined diagnosis.
  • [MeSH-major] Cytodiagnosis / methods. Immunohistochemistry / methods. Neoplasm, Residual / diagnosis. Uterine Cervical Neoplasms / diagnosis


42. Macdonald OK, Sause WT, Lee RJ, Dodson MK, Zempolich K, Gaffney DK: Does oncologic specialization influence outcomes following surgery in early stage adenocarcinoma of the endometrium? Gynecol Oncol; 2005 Dec;99(3):730-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does oncologic specialization influence outcomes following surgery in early stage adenocarcinoma of the endometrium?
  • OBJECTIVE: To evaluate treatment outcomes in women with early-stage endometrial cancer (FIGO IA, IB, IC, or IIA) surgically managed by a general gynecologist (GYN) or a gynecologic oncologist (GYO).
  • [MeSH-major] Adenocarcinoma / surgery. Endometrial Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16139348.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Lin F, Shi J, Liu H, Zhang J, Zhang PL, Wang HL, Yang XJ, Schuerch C: Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus. Am J Clin Pathol; 2008 Apr;129(4):592-605
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus.
  • Genetic alteration of the von Hippel-Lindau (VHL) tumor suppressor gene has been linked to hereditary and sporadic clear cell renal cell carcinomas (RCCs).
  • Positive immunostaining was observed in nearly 100% of primary renal neoplasms, 95% of metastatic RCCs, and 90% of clear cell carcinomas of the ovary and uterus.
  • These data indicate that this anti-pVHL antibody is a useful marker in assisting diagnosis of metastatic RCC and may serve as a diagnostic marker for clear cell carcinomas of the ovary and uterus.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Ovarian Neoplasms / metabolism. Uterine Neoplasms / metabolism. Von Hippel-Lindau Tumor Suppressor Protein / metabolism


44. Drljević K, Mehmedbasić S: [The frequency of female genital cancer at Gynecological Department in Cantonal Hospital Zenica--before, during and postwar time in Bosnia-Herzegovina]. Med Arh; 2005;59(3):183-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The frequency of female genital cancer at Gynecological Department in Cantonal Hospital Zenica--before, during and postwar time in Bosnia-Herzegovina].
  • The most frequent type of malign tumour is carcinoma with the frequency of over 98% (70.06% carcinoma planocellulare, 27.86 adenocarcinoma), while recently literature shows a bit over 90% of frequency.
  • Results show that approximately 9/10 of all malign processes in female genital tract occurred at uterus.
  • Malign diseases, due to cervical cancer, which encumbers more than half of the cases, mostly afflict age group of 35-49, while the age group 50-64 is mostly afflicted by corporal and ovarian malign tumours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15997680.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


46. Zhou J, Shen K, Zeng JF, Yang JX, Cao DY, Cui QC: [Differential expression of microRNAs associated with estrogen receptor alpha and progesterone receptor in typeIand typeII endometrial adenocarcinomas.]. Zhonghua Fu Chan Ke Za Zhi; 2009 Oct;44(10):765-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential expression of microRNAs associated with estrogen receptor alpha and progesterone receptor in typeIand typeII endometrial adenocarcinomas.].
  • OBJECTIVE: To identify differentially expression of microRNAs associated with expression of estrogen receptor alpha (ERalpha) and progesterone receptor (PR) between type I and type II endometrial adenocarcinoma.
  • METHODS: Two kinds of endometrial adenocarcinoma cell lines, Ishikawa and KLE, was transplanted into nude mice and biopsied to identify the expression of ERalpha, PR and p53, and test their response to estrogen and progesterone.
  • RESULTS: Ishikawa cell line was confirmed from type I endometrial adenocarcinoma, KLE cell line was confirmed from type II endometrial adenocarcinoma.
  • CONCLUSION: Hsa-miR-100 is significantly down-expressed in type I endometrial adenocarcinoma compared to type II, which may be a great potential to target ESR1.
  • [MeSH-minor] Adenocarcinoma / genetics. Animals. Endometrial Neoplasms. Estrogen Receptor alpha / metabolism. Gene Expression Regulation, Neoplastic. Humans. Mice, Nude

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20078964.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / MicroRNAs; 0 / Receptors, Progesterone
  •  go-up   go-down


47. Sales KJ, Maldonado-Pérez D, Grant V, Catalano RD, Wilson MR, Brown P, Williams AR, Anderson RA, Thompson EA, Jabbour HN: Prostaglandin F(2alpha)-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway. Biochim Biophys Acta; 2009 Dec;1793(12):1917-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostaglandin F(2alpha)-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway.
  • Recently we showed elevated expression of the chemokine (C-X-C motif) receptor 2 (CXCR2) in endometrial adenocarcinomas localized to neutrophils and neoplastic epithelial and vascular cells.
  • Furthermore we found that PGF(2alpha)-F-prostanoid (FP) receptor regulates the expression of the CXCR2 ligand CXCL1, to promote neutrophil chemotaxis in endometrial adenocarcinomas.
  • In the present study we identified another CXCR2 ligand, CXCL8 as a target for PGF(2alpha)-FP receptor signalling which enhances epithelial cell proliferation in endometrial adenocarcinoma cells in vitro and in nude mice in vivo.
  • We found that PGF(2alpha)-FP receptor interaction induces CXCL8 expression in endometrial adenocarcinoma cells via the protein kinase C-calcium-calcineurin-NFAT signaling pathway.
  • Using an adenovirus to overexpress RCAN1-4, we found that RCAN1-4 is a negative regulator of CXCL8 expression in endometrial adenocarcinoma cells.
  • Taken together our data have elucidated the molecular and cellular mechanism whereby PGF(2alpha) regulates CXCL8 expression via the FP receptor in endometrial adenocarcinomas and have highlighted RCAN1-4 as a negative regulator of CXCL8 expression which may be exploited therapeutically to inhibit CXCL8-mediated tumour development.
  • [MeSH-major] Adenocarcinoma / metabolism. Calcineurin / metabolism. Calcium / metabolism. Endometrial Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Interleukin-8 / biosynthesis. NFATC Transcription Factors / metabolism. Neoplasm Proteins / metabolism. Receptors, Prostaglandin / metabolism. Signal Transduction

  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2373-80 [17893866.001]
  • [Cites] FASEB J. 2007 Oct;21(12):3023-8 [17595344.001]
  • [Cites] Cytokine. 2008 Mar;41(3):232-9 [18182303.001]
  • [Cites] Mol Cell Endocrinol. 2008 Mar 26;285(1-2):51-61 [18316157.001]
  • [Cites] Oral Oncol. 2008 Oct;44(10):920-6 [18282785.001]
  • [Cites] Biochim Biophys Acta. 2009 Jul;1793(7):1315-24 [19348862.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5726-33 [19549892.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1221-36 [10582349.001]
  • [Cites] J Immunol. 2000 Jun 1;164(11):5944-51 [10820277.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):357-64 [11162945.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4893-8 [11320240.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21797-808 [11259418.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2476-89 [11402342.001]
  • [Cites] Oncogene. 2001 May 17;20(22):2771-80 [11420689.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1023-31 [11592775.001]
  • [Cites] Am J Reprod Immunol. 2002 Apr;47(4):213-21 [12069388.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):125-34 [12107097.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Reproduction. 2003 Nov;126(5):559-67 [14611628.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):986-93 [14764825.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1030-43 [15057743.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 18;101(20):7554-9 [15131267.001]
  • [Cites] Bioorg Med Chem. 2004 Jun 15;12(12):3125-33 [15158780.001]
  • [Cites] Trends Endocrinol Metab. 2004 Oct;15(8):398-404 [15380812.001]
  • [Cites] J Cell Physiol. 1986 Dec;129(3):375-84 [3465735.001]
  • [Cites] J Pharmacol Exp Ther. 1990 Nov;255(2):756-68 [2147038.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):1-16 [2026352.001]
  • [Cites] Cancer Surv. 1994;19-20:287-307 [7895220.001]
  • [Cites] J Biol Chem. 1995 Jun 16;270(24):14255-8 [7782278.001]
  • [Cites] Biol Chem Hoppe Seyler. 1996 Jun;377(6):373-84 [8839983.001]
  • [Cites] J Biol Chem. 1996 Oct 25;271(43):27018-24 [8900190.001]
  • [Cites] Chem Biol. 1996 Dec;3(12):981-91 [9000009.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1996 Dec;70(1):15-7 [9031912.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):4919-24 [9144165.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1201-5 [9543141.001]
  • [Cites] J Biol Chem. 1998 Apr 24;273(17):10095-8 [9553055.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1783-7 [9589693.001]
  • [Cites] Hum Reprod. 1998 Aug;13(8):2292-5 [9756313.001]
  • [Cites] Mol Endocrinol. 1999 Feb;13(2):276-85 [9973257.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2435-8 [10051660.001]
  • [Cites] Gastroenterol Clin North Am. 1999 Jun;28(2):459-77, x [10372277.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Sep;290(3):1278-84 [10454504.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):47438-45 [15339913.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50537-54 [15448146.001]
  • [Cites] Hum Reprod. 2005 Mar;20(3):794-801 [15618253.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7707-16 [16140938.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13075-80 [16131541.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4198-207 [16618742.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):941-51 [16567391.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3635-44 [17478553.001]
  • [Cites] Endocr Relat Cancer. 2007 Dec;14(4):1039-52 [18045955.001]
  • (PMID = 19819266.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127684438; United Kingdom / Medical Research Council / / U.1276.00.004.00002.01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / IL8 protein, human; 0 / Interleukin-8; 0 / NFATC Transcription Factors; 0 / Neoplasm Proteins; 0 / Receptors, Prostaglandin; 0 / prostaglandin F2alpha receptor; B7IN85G1HY / Dinoprost; EC 2.7.11.13 / Protein Kinase C; EC 3.1.3.16 / Calcineurin; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2806519
  •  go-up   go-down


48. Koshiba H, Hosokawa K, Kubo A, Tokumitsu N, Watanabe A, Honjo H: Junctional adhesion molecule A [corrected] expression in human endometrial carcinoma. Int J Gynecol Cancer; 2009 Feb;19(2):208-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Junctional adhesion molecule A [corrected] expression in human endometrial carcinoma.
  • Loss of cell adhesion molecules may be associated with high histologic grade and invasiveness of endometrial carcinoma.
  • We attempted to determine JAM-A expression in human endometrial carcinoma and its correlations with pathologic features, stage, and survival.
  • Junctional adhesion molecule A expression in human endometrial carcinoma was evaluated by immunohistochemistry.
  • In addition, we cultured human well and poorly differentiated endometrial adenocarcinoma cell lines, Ishikawa cells, and KLE in 3-dimensional basement membrane preparation, and JAM-A expression in these cells was assessed by real-time reverse transcription-polymerase chain reaction and immunohistochemistry.
  • Additionally, in our 3-dimensional epithelial cell culture, JAM-A expression in poorly differentiated adenocarcinoma was significantly lower than that in well-differentiated adenocarcinoma (P < 0.001).
  • Junctional adhesion molecule A expression seems to be reduced in high-grade or advanced endometrial carcinoma and may be a prognostic factor.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Adhesion Molecules / biosynthesis. Endometrial Neoplasms / metabolism. Immunoglobulins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Cancer. 2009 Aug;19(6):1153
  • (PMID = 19395995.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / F11R protein, human; 0 / Immunoglobulins; 0 / Receptors, Cell Surface
  •  go-up   go-down


49. Bharwani N, Newland A, Tunariu N, Babar S, Sahdev A, Rockall AG, Reznek RH: MRI appearances of uterine malignant mixed müllerian tumors. AJR Am J Roentgenol; 2010 Nov;195(5):1268-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI appearances of uterine malignant mixed müllerian tumors.
  • OBJECTIVE: Uterine malignant mixed müllerian tumors (MMMTs) are rare aggressive tumors with a high incidence of lymphatic, peritoneal, and pulmonary metastases.
  • Preoperative differentiation from endometrial adenocarcinoma would be beneficial because their prognoses differ.
  • Data were compared with MRI appearances of 73 endometrial adenocarcinomas.
  • RESULTS: On T1-weighted images, MMMTs were predominantly isointense to myometrium (76%) and endometrium (71%), with heterogeneous texture in 33% of cases and hyperintense foci in 27% of cases.
  • On T2-weighted images, 92% of MMMTs were hyperintense to myometrium and either hypointense (55%) or isointense (41%) to endometrium.
  • In 12% of cases, large heterogeneous MMMTs obliterated uterine architecture and were aggressive in appearance, whereas in 88% of cases, the appearances were indistinguishable from those of endometrial adenocarcinoma.
  • Significantly more MMMTs than endometrial adenocarcinomas had cervical invasion (p = 0.008) and nodal enlargement (p = 0.00008).
  • This finding is significantly different from that for endometrial adenocarcinoma, where enhancement is less than that of myometrium in 90% of cases (p = 4 × 10⁻⁸).
  • [MeSH-major] Magnetic Resonance Imaging / methods. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Aged, 80 and over. Chi-Square Distribution. Contrast Media. Endometrial Neoplasms / pathology. Female. Humans. Meglumine. Middle Aged. Organometallic Compounds. Retrospective Studies

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20966339.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 0 / gadoterate meglumine; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


50. Sztanke K, Tuzimski T, Rzymowska J, Pasternak K, Kandefer-Szerszeń M: Synthesis, determination of the lipophilicity, anticancer and antimicrobial properties of some fused 1,2,4-triazole derivatives. Eur J Med Chem; 2008 Feb;43(2):404-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compounds 7 and 12 were evaluated for their cytotoxic activity against three cancer cell lines: human Caucasian colon adenocarcinoma cell line - LS180 (ECACC 87021202), human uterus carcinoma cell line - SiHa (ECACC 85060701) and human breast carcinoma cell line - T47D (ECACC 85102201).
  • Compound 12 was found to be the most effective in vitro against human colon adenocarcinoma cell line (LS180).
  • Moreover, the distinctly marked lower cytotoxicity of compounds 7 and 12 against the normal cell line - human skin fibroblasts (HSF) and almost several-fold higher against the examined cancer cell lines was ascertained.
  • The cytotoxic effect of imidazotriazole 7 was noticed on DNA structure of breast cancer cell line (T47D) by using the comet assay.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17531354.001).
  • [ISSN] 0223-5234
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antineoplastic Agents; 0 / Lipids; 0 / Triazoles
  •  go-up   go-down


51. Yang X, Dong Y, Zhao J, Sun H, Deng Y, Fan J, Yan Q: Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma. Pathol Res Pract; 2007;203(7):499-505
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma.
  • To evaluate the association between the expression of human macrophage metalloelastase (matrix metalloproteinase-12, MMP-12) with cancer invasion and differentiation of endometrial adenocarcinoma, specimens from endometrial adenocarcinoma (n=61) of diverse stages and histologic types were collected from patients having undergone hysterectomy, and specimens from normal endometrium (n=38) were obtained from patients with benign diseases.
  • The positive rate of MMP-12 was significantly increased in endometrial adenocarcinoma (81.97%) as compared with that in normal endometrium (13.16%).
  • The results showed that expression of MMP-12 correlated with stage (p=0.022) and grade (p=0.018) of endometrial cancer.
  • MMP-12 immunoreactive proteins were found mainly on the glandular epithelial cells of endometrial adenocarcinoma.
  • The macrophage infiltration detected by CD68 immunohistochemical staining in endometrial adenocarcinoma was also higher than that in normal endometrium.
  • In this study, we show that in addition to macrophages, endometrial adenocarcinoma cells are able to express MMP-12.
  • Increased MMP-12 expression tended to be associated with the extent of adenocarcinoma invasion accompanied by marked macrophage infiltration.
  • Our results suggest that MMP-12 is an important oncogene in high-stage and high-grade endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. Matrix Metalloproteinase 12 / biosynthesis. Neoplasm Invasiveness / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17574772.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; EC 3.4.24.65 / Matrix Metalloproteinase 12
  •  go-up   go-down


52. Hanley KZ, Tadros TS, Briones AJ, Birdsong GG, Mosunjac MB: Hematologic malignancies of the female genital tract diagnosed on liquid-based Pap test: Cytomorphologic features and review of differential diagnoses. Diagn Cytopathol; 2009 Jan;37(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical symptoms are often nonspecific and mimic other more common gynecologic malignancies such as squamous cell carcinoma of the cervix or endometrial adenocarcinoma.
  • Although cervico-vaginal (Pap) smear is the primary screening method for cervical squamous cell carcinoma and its precursors, it is far less sensitive for detection of other primary or metastatic malignancies.
  • In this review, we present three cases of hematologic gynecologic malignancies, two cases of primary NHL, and a case of acute myeloid leukemia with relapse as a pelvic mass, all of which were diagnosed on a liquid-based Pap test.
  • In addition, we discuss the morphologic features of differential diagnostic entities of these rare tumors on conventional and liquid-based preparations.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Papanicolaou Test. Vaginal Smears


53. Lehmann L, Wagner J, Metzler M: Estrogenic and clastogenic potential of the mycotoxin alternariol in cultured mammalian cells. Food Chem Toxicol; 2006 Mar;44(3):398-408
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AOH replaced E2 from isolated human estrogen receptors alpha and beta and increased the level of alkaline phosphatase (ALP) mRNA and the enzymatic activity of ALP in a human endometrial adenocarcinoma cell line (Ishikawa cells).
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / metabolism. Alternaria / metabolism. Animals. Cell Line, Tumor. Chromosome Aberrations. Cricetinae. Cricetulus. Dose-Response Relationship, Drug. Endometrial Neoplasms / enzymology. Endometrial Neoplasms / metabolism. Enzyme Induction. Esophageal Neoplasms / chemically induced. Estrogen Receptor alpha / metabolism. Estrogen Receptor beta / metabolism. Female. Flow Cytometry. Food Contamination. Humans. Male. Micronucleus Tests. RNA, Messenger / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194592.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholinesterase Inhibitors; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Estrogens; 0 / Lactones; 0 / Mutagens; 0 / RNA, Messenger; EC 3.1.3.1 / Alkaline Phosphatase; KN9L4260JW / alternariol
  •  go-up   go-down


54. Li ZL, Morishima S, Tang JT, Otsuki Y: Apoptotic effects of Tian-Long compound on endometrial adenocarcinoma cells in vitro. Med Mol Morphol; 2009 Mar;42(1):32-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic effects of Tian-Long compound on endometrial adenocarcinoma cells in vitro.
  • To explore its antitumor properties and the mechanism for activity in gynecological malignancies, the present studies were carried out using Ishikawa cells derived from uterine endometrial adenocarcinoma.
  • The present results indicate that the ingredients of TL compound are very promising for use in the treatment of endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Drugs, Chinese Herbal / pharmacology. Endometrial Neoplasms / drug therapy. Phytotherapy

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Rev Cytol. 1980;68:251-306 [7014501.001]
  • [Cites] J Histochem Cytochem. 2003 Dec;51(12):1601-9 [14623928.001]
  • [Cites] J Nat Prod. 2001 Mar;64(3):286-8 [11277740.001]
  • [Cites] Med Mol Morphol. 2008 Mar;41(1):34-43 [18470679.001]
  • [Cites] Cell Stress Chaperones. 1998 Dec;3(4):213-20 [9880233.001]
  • [Cites] Cancer Res. 1993 May 1;53(9):2133-9 [8481916.001]
  • [Cites] Am J Chin Med. 1994;22(2):137-45 [7992813.001]
  • [Cites] Food Chem Toxicol. 2003 Oct;41(10 ):1421-8 [12909277.001]
  • [Cites] Pathol Annu. 1982;17 Pt 2:229-59 [7182752.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):327-32 [15251124.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1456-62 [7878464.001]
  • [Cites] Med Mol Morphol. 2008 Sep;41(3):132-8 [18807138.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):5870-8 [2790800.001]
  • [Cites] Lancet. 1994 Jul 2;344(8914):28-9 [7912299.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1028:150-6 [15650241.001]
  • [Cites] J Leukoc Biol. 1993 Nov;54(5):407-13 [8228619.001]
  • [Cites] Biochem Syst Ecol. 2000 Jun 1;28(5):403-419 [10725598.001]
  • [Cites] J Ethnopharmacol. 1999 Nov 1;67(2):163-9 [10619380.001]
  • [Cites] World J Gastroenterol. 2003 Sep;9(9):1963-7 [12970885.001]
  • [Cites] Toxicol Appl Pharmacol. 1994 Oct;128(2):169-81 [7940532.001]
  • [Cites] J Pharmacobiodyn. 1990 Jul;13(7):426-31 [2290126.001]
  • [Cites] Hum Cell. 2002 Sep;15(3):104-17 [12703541.001]
  • (PMID = 19294490.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / DNA, Neoplasm; 0 / Drugs, Chinese Herbal; 0 / Phosphatidylserines; 0 / Proto-Oncogene Proteins c-bcl-2; 4TI98Z838E / Estradiol; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


55. Larbcharoensub N, Lertkhachonsuk AA, Rochanawutanon M: Secondary vaginal involvement following radical surgical treatment for a stage I ovarian adenocarcinoma arising in mature cystic teratoma. J Med Assoc Thai; 2007 Oct;90(10):2209-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary vaginal involvement following radical surgical treatment for a stage I ovarian adenocarcinoma arising in mature cystic teratoma.
  • BACKGROUND: Vaginal carcinoma represents 1-2% of all gynecologic malignancies.
  • Most cases reported secondary involvement from adjacent organs including cervix, uterus, and colorectum.
  • Vaginal involvement from adenocarcinoma arising in mature cystic teratoma (MCT) has never been reported.
  • She had had a history of right ovarian adenocarcinoma arising in MCT, FIGO stage IC, for 18 months' duration.
  • Incisional biopsy of the vaginal lesion revealed adenocarcinoma, morphologically and immunohistologically identical to the right oophorectomized specimen.
  • CONCLUSION: Adenocarcinoma is rarely found in MCT.
  • This is the first case of ovarian adenocarcinoma arising in MCT with secondary vaginal involvement, presenting as postcoital vaginal bleeding.
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Carboplatin / therapeutic use. Disease Progression. Female. Humans. Immunohistochemistry. Paclitaxel / therapeutic use. Teratoma / surgery. Thailand

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18041444.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


56. Fuentes Dehesa M, Arteaga Gómez AC, Moreno Verduzco E, Aranda Flores CE: [Pregnancy after conservative management of endometrial cancer]. Ginecol Obstet Mex; 2009 Sep;77(9):419-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pregnancy after conservative management of endometrial cancer].
  • [Transliterated title] Embarazo después del tratamiento conservador de cáncer de endometrio.
  • OBJECTIVE: To show the reproductive future of a case of endometrial cancer with conservative management.
  • 31 years old woman, with a history of infertility of three years and abnormal uterine bleeding of one year, diagnosed with well differentiated endometrial adenocarcinoma IA GI.
  • Treatment was initiated with 500 mg of progesterone three times a week for 6 months, after an endometrial curettage reporting healthy endometrium, pregnancy was achieved with homologous artificial insemination after hysteroscopy and directed biopsy with laparoscopic control by assisted reproduction service.
  • CONCLUSIONS: Endometrial cancer is common in adult women and is increasingly affecting young women, associated with infertility, obesity and nulliparity.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy. Pregnancy Outcome

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19899431.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 6
  •  go-up   go-down


57. Chen F, Shen K, Lang JH, Huang HF, Wu M: [Clinical features and prognostic of double primary carcinoma of uterine corpus and the ovary]. Zhonghua Yi Xue Za Zhi; 2005 May 18;85(18):1257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognostic of double primary carcinoma of uterine corpus and the ovary].
  • OBJECTIVE: To investigate the clinical features, treatment and prognosis of patients with double primary carcinoma of uterine corpus and ovary.
  • METHODS: The clinical features, operation findings, treatment and prognosis of 36 patients with double primary carcinoma of uterine corpus diagnosed and treated in the last 20 years, 25 with typical endometrial adenocarcinoma and endometrioid carcinoma of the ovary (group A) 11 with non-endometrioid carcinoma in uterine corpus and/or ovary (group B) were respectively analyzed.
  • RESULTS: There was no significant difference in survival rate between the group A and group B.
  • The 1, 3, and 5-year survival rates of these 36 patients were 89%, 83%, and 75% respectively, all equal to those of the patients with stage I ovarian cancer.
  • CONCLUSION: The prognosis of double primary carcinoma of uterine corpus and ovary is rather good.
  • It is necessary to distinguish double primary carcinoma of uterine corpus and ovary from stage II ovarian cancer and stage III endometrial carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029611.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


58. Wu HM, Lai CH, Huang HY, Wang HS, Soong YK: A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer. Chang Gung Med J; 2008 Jan-Feb;31(1):102-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer.
  • Endometrial cancer is predominately a postmenopausal disease.
  • Endometrial cancer in women of childbearing age is relatively unusual.
  • Endometrial cancer is typically treated with hysterectomy.
  • After the development of endometrial cancer, successful pregnancy is rare.
  • We present a case of recurrent stage I endometrial adenocarcinoma in a 35-year-old woman.
  • Magnetic resonance imaging (MRI) revealed endometrial lesions without myometrium invasion and no pelvic lymph node enlargement.
  • On the basis of these observations and the low malignant potential of well-differentiated endometrial carcinoma, fertility-preserving treatment using Megace therapy was suggested.
  • Recurrent endometrial adenocarcinoma was documented using hysteroscopy and direct endometrial biopsy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Endometrial Neoplasms / drug therapy. Fertilization in Vitro. Megestrol Acetate / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Twins

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18419059.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


59. Indraccolo U, Cingolani N, Indraccolo SR: Bilateral Brenner tumor with endometrial adenocarcinoma in a postmenopausal woman. Eur J Gynaecol Oncol; 2007;28(3):233-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral Brenner tumor with endometrial adenocarcinoma in a postmenopausal woman.
  • Brenner tumor is a rare ovarian neoplasm which is generally monolateral, more rarely bilateral, and often associated with endometrial disorders related to oestrogenic production.
  • However, there is no considerable evidence that the possible oestrogenic production of this tumor may be the cause of endometrial disorders.
  • A case of bilateral Brenner tumor with endometrial adenocarcinoma in a postmenopausal woman is presented and the features are briefly discussed, with the conclusion that hormone-producing Brenner tumors may exert their promoter effect on the development of endometrial carcinoma causing an imbalance in the oestrogen and progesterone ratio rather than producing a large amount of oestrogen.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Endometrioid / pathology. Endometrial Stromal Tumors / pathology. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Postmenopause

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624095.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


60. Maxwell GL, Tian C, Risinger J, Brown CL, Rose GS, Thigpen JT, Fleming GF, Gallion HH, Brewster WR, Gynecologic Oncology Group study: Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer; 2006 Nov 1;107(9):2197-205
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study.
  • BACKGROUND: Previous studies have reported shorter survival of black women compared with white women who had advanced/recurrent endometrial cancer.
  • METHODS: The authors retrospectively reviewed data from 169 black women and 982 white women with International Federation of Gynecologic Oncology (FIGO) Stage III, Stage IV, or recurrent endometrial carcinoma who were participants in 1 of 4 Gynecologic Oncology Group randomized treatment trials of doxorubicin alone or combined with paclitaxel and/or cisplatin.
  • CONCLUSIONS: The data from a large group of women with advanced/recurrent endometrial cancer suggested that a racial disparity in survival persists, despite the finding that black women and white women received similar treatment.
  • Although the causes of racial disparity in endometrial cancer remain to be elucidated, socioeconomic, biologic, and cultural factors should be investigated to identify the etiologic origins of this multifactorial healthcare problem.
  • [MeSH-major] Adenocarcinoma / ethnology. African Americans. Endometrial Neoplasms / ethnology. European Continental Ancestry Group. Neoplasm Recurrence, Local / ethnology

  • MedlinePlus Health Information. consumer health - African American Health.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001661.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


61. Geldenhuys L, Murray ML: Sensitivity and specificity of the Pap smear for glandular lesions of the cervix and endometrium. Acta Cytol; 2007 Jan-Feb;51(1):47-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and specificity of the Pap smear for glandular lesions of the cervix and endometrium.
  • OBJECTIVE: To investigate the sensitivity and specificity of the Pap smear for detection of adenocarcinoma in situ of the cervix (AIS), endocervical adenocarcinoma (ECAC) and endometrial adenocarcinoma (EAC) as well as the overall specificity of the smear for detection of glandular lesions in general.
  • Computer records were also searched for patients who had a Pap smear result consisting of suspicious or positive for AIS or adenocarcinoma (AC) with subsequent tissue diagnosis during the same time.
  • RESULTS: One hundred percent of patients with AIS, 80% with ECAC and 22% with EAC on histology had positive findings on a Pap smear performed within a year of the histologic diagnosis.
  • It also confirmed the good sensitivity for glandular lesions of the cervix and the poor sensitivity for glandular lesions of the endometrium.
  • It thus confirmed that the Pap smear is not an effective screening tool for endometrial AC, and that the quest for alternative screening methods should continue.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Carcinoma in Situ. Cervical Intraepithelial Neoplasia / diagnosis. Female. Humans. Sensitivity and Specificity. Uterine Hemorrhage / diagnosis


62. Xiong Y, Dowdy SC, Gonzalez Bosquet J, Zhao Y, Eberhardt NL, Podratz KC, Jiang SW: Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol Oncol; 2005 Oct;99(1):135-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines.
  • OBJECTIVES: To determine if epigenetic interference can restore progesterone receptor-B (PR-B) expression in PR-B negative endometrial adenocarcinoma cell lines, and to characterize the kinetics of PR-B induction mediated by DNA methyltransferase and histone deacetylase inhibitors.
  • METHODS: The PR-B negative endometrioid cancer cell lines KLE and HEC-1B were used as study models.
  • CONCLUSION: The epigenetically silenced PR-B gene remains sensitive to changes in DNA demethylation and histone acetylation in uterine adenocarcinoma cell lines.
  • These small molecule epigenetic modifying agents may be used to sensitize poorly differentiated, PR-B negative endometrial cancers to progestational therapy.
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Receptors, Progesterone / genetics

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024066.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 0 / progesterone receptor B; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; EC 3.5.1.98 / Histone Deacetylases; M801H13NRU / Azacitidine
  •  go-up   go-down


63. Wang XY, Pan ZM, Chen XD, Lü WG, Xie X: Accuracy of tumor grade by preoperative curettage and associated clinicopathologic factors in clinical stage I endometriod adenocarcinoma. Chin Med J (Engl); 2009 Aug 20;122(16):1843-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of tumor grade by preoperative curettage and associated clinicopathologic factors in clinical stage I endometriod adenocarcinoma.
  • BACKGROUND: Preoperative tumor grading becomes one of the most important predictors for lymphadenectomy at primary surgery for clinical stage I endometriod adenocarcinoma.
  • This study aimed to evaluate the accuracy of tumor grade by preoperative curettage so as to achieve a better stratified management for clinical stage I endometriod adenocarcinoma.
  • METHODS: Clinical data of totally 687 patients with clinical stage I endometriod adenocarcinoma who underwent preoperative curettage and primary surgery were retrospectively collected.
  • Compared with final hysterectomy specimens, the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of tumor grade by preoperative curettage were calculated and their associations with clinicopathologic parameters, including age, status of menopause, position of uterus, location and size of lesion, histological grade, depth of myometrial invasion, cervical invasion, extrauterine spread, peritoneal cytology, metastasis to retroperitoneal lymph node, serum CA125 level, and hormone receptor status, were analyzed.
  • Complete surgical staging seems to be necessary for clinical stage I endometriod adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Curettage / methods. Endometrial Neoplasms / diagnosis. Neoplasm Staging / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781357.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


64. Vaidya AP, Horowitz NS, Oliva E, Halpern EF, Duska LR: Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol; 2006 Nov;103(2):684-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
  • OBJECTIVE: Uterine mixed malignant mullerian tumors (MMMT) have traditionally been excluded from clinical trials of endometrial cancer because of a belief that they are more correctly included in the sarcoma category.
  • Recently, investigators have suggested that uterine MMMTs are actually dedifferentiated epithelial tumors and should be treated as such.
  • The current study was undertaken to compare outcomes, stage for stage, of uterine MMMT with poor prognosis endometrial adenocarcinomas.
  • Cases were matched by age, stage, performance status, and surgical procedure to controls consisting of grade 3 endometrioid, papillary serous, and clear cell endometrial carcinomas from the same time period.
  • Of the controls, 31 (69%) had grade 3 endometrioid, 11 (24%) papillary serous, and 3 (7%) clear cell carcinoma.
  • CONCLUSIONS: Patients with uterine MMMT have a poorer prognosis than those patients with high grade epithelial tumors, especially for those with early stage disease.
  • Given the discrepancy in survival, these patients should not be included in studies of endometrial carcinoma.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Mixed Tumor, Mullerian / pathology. Mixed Tumor, Mullerian / therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Case-Control Studies. Chemotherapy, Adjuvant. Female. Humans. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies


65. Liao CL, Hsu JD, Lee MY, Kok LF, Li YJ, Wang PH, Yao CC, Han CP: Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough? Virchows Arch; 2010 Apr;456(4):377-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough?
  • Gynecological pathologists are used to operating many panels of various markers in combination for the diagnostic distinction between primary endocervical and endometrial adenocarcinomas.
  • A tissue microarray was constructed using paraffin-embedded, formalin-fixed tissues from 35 hysterectomy specimens, including 14 primary endocervical adenocarcinomas and 21 primary endometrial adenocarcinomas.
  • However, one panel of 2-markers (Vim, CEA) exhibited the most efficiency (78.3%) in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas.
  • Based on the analyzed data, we conclude that the 2-marker (Vim/CEA) panel seems adequate to be an appropriate, convenient, and efficient means to distinguish between primary endocervical and endometrial adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Endometrial Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vimentin / metabolism
  • [MeSH-minor] Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. Protein Array Analysis / methods. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):974 [15223971.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):217-23 [12068166.001]
  • [Cites] J Exp Clin Cancer Res. 2008 Aug 02;27:25 [18673574.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] Int J Gynecol Pathol. 2009 Sep;28(5):489-96 [19696622.001]
  • [Cites] Arch Pathol Lab Med. 2008 Mar;132(3):402-23 [18318583.001]
  • [Cites] Arch Gynecol Obstet. 2009 Sep;280(3):405-13 [19153755.001]
  • [Cites] BMC Clin Pathol. 2006 Jan 12;6:1 [16409624.001]
  • [Cites] Mod Pathol. 2009 Jun;22(6):797-806 [19347018.001]
  • [Cites] Radiology. 2002 May;223(2):410-6 [11997546.001]
  • [Cites] Virchows Arch. 2003 Mar;442(3):271-7 [12647218.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):231-5 [12819388.001]
  • [Cites] Virchows Arch. 2009 Oct;455(4):353-61 [19763614.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1091-100 [16648864.001]
  • [Cites] Semin Nucl Med. 1978 Oct;8(4):283-98 [112681.001]
  • [Cites] Arch Gynecol Obstet. 2010 May;281(5):845-50 [19847454.001]
  • [Cites] Curr Treat Options Oncol. 2004 Apr;5(2):119-27 [14990206.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jul;27(3):431-6 [18580323.001]
  • [Cites] Adv Anat Pathol. 2004 May;11(3):162-71 [15096730.001]
  • [Cites] J Transl Med. 2008 Jun 17;6:31 [18559092.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):160-7 [15043304.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):172-7 [8617459.001]
  • [Cites] J Negat Results Biomed. 2007 Apr 25;6:6 [17459164.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):4-10 [11781516.001]
  • (PMID = 20221633.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vimentin
  •  go-up   go-down


66. Parini CL, Mathis D, Leath CA 3rd: Occult metastatic lung carcinoma presenting as locally advanced uterine carcinosarcoma on positron emission tomography/computed tomography imaging. Int J Gynecol Cancer; 2007 May-Jun;17(3):731-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult metastatic lung carcinoma presenting as locally advanced uterine carcinosarcoma on positron emission tomography/computed tomography imaging.
  • A 73-year-old postmenopausal female with stage IV nonsmall cell lung cancer presented after a PET/CT demonstrated focal uptake in the superior and lateral aspects of the uterus.
  • The patient reported a history of intermittent postmenopausal bleeding and an endometrial biopsy documented uterine carcinosarcoma.
  • Postoperative pathologic review and immunohistochemical staining with thyroid transcription factor-1 revealed metastatic adenocarcinoma consistent with her lung primary in her uterus and adnexa.
  • Our case represents a rare occurrence in which lung cancer has metastasized to multiple female pelvic organs.
  • [MeSH-major] Carcinoma / pathology. Carcinosarcoma / radiography. Carcinosarcoma / secondary. Lung Neoplasms / pathology. Neoplasms, Unknown Primary / radiography. Uterine Neoplasms / radiography. Uterine Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504386.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Hoffman MS, Williams V, Salihu HM, Gunasekaran S, Sayer RA, Hakam A, Roberts WS: The vascular portion of the cardinal ligament: surgical significance during radical hysterectomy for cervical cancer. Am J Obstet Gynecol; 2008 Aug;199(2):191.e1-7; discussion 191.e7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The vascular portion of the cardinal ligament: surgical significance during radical hysterectomy for cervical cancer.
  • OBJECTIVE: The objective of the study was to analyze the histopathologic content of the vascular portion of the cardinal ligament in patients undergoing radical hysterectomy for cervical cancer.
  • CONCLUSION: Among a population of women with high-risk, early-stage cervical cancer, the lateral vascular segment of the cardinal ligament contained metastatic disease in a substantial number of patients.
  • [MeSH-major] Hysterectomy / methods. Ligaments / blood supply. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery. Uterus / blood supply
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Female. Humans. Lymphatic Metastasis. Middle Aged


68. Wang HY, Shen L, Sun Z: [Endometrial adenocarcinoma in women 40 years old or younger by treatment with progestins: report of 6 cases and review of the literatures]. Zhonghua Fu Chan Ke Za Zhi; 2006 Apr;41(4):237-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrial adenocarcinoma in women 40 years old or younger by treatment with progestins: report of 6 cases and review of the literatures].
  • OBJECTIVE: To evaluate the effectiveness and safety of fertility-sparing treatment with progestins in patients with well-differentiated endometrial adenocarcinoma in women 40 years old or younger.
  • METHODS: Six patients before the age of 40 diagnosed with grade I endometrial adenocarcinoma, who had undergone primary progestin treatment, were retrospectively studied.
  • Relevant articles describing patients with endometrial adenocarcinoma who were treated with hormonal therapy were searched.
  • RESULTS: Four of six cases responded to treatment with normal pathology on follow-up endometrial samplings.
  • CONCLUSIONS: Progestin treatment is proved a safe and feasible therapy in well-differentiated endometrial adenocarcinoma in women 40 years old or younger.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Progestins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16759457.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Progestins
  • [Number-of-references] 22
  •  go-up   go-down


69. Qian J, Weber D, Cochran R, Hossain D, Bostwick DG: Detection of chromosomal anomalies in endometrial atypical hyperplasia and carcinoma by using fluorescence in situ hybridization. Cancer Cytopathol; 2010 Apr 25;118(2):97-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of chromosomal anomalies in endometrial atypical hyperplasia and carcinoma by using fluorescence in situ hybridization.
  • BACKGROUND: Endometrial cancer is the most common pelvic gynecological malignancy.
  • The diagnosis of well-differentiated endometrial adenocarcinoma, atypical hyperplasia, and hyperplasia is often challenging.
  • The authors sought to investigate the utility of chromosomal anomalies for the detection of endometrial hyperplasia and carcinoma using multitarget fluorescence in situ hybridization (FISH).
  • METHODS: Samples were collected by endometrial Tao brush and processed by liquid-based cytological preparation protocol from consecutive cases to include 50 benign, 50 hyperplasia without atypia, 47 atypical hyperplasia, and 53 endometrial cancers.
  • The FISH signals were enumerated in 100 cells per case, and the chromosomal anomalies were correlated with pathologic findings, including histologic diagnoses on matched endometrial tissue samples.
  • RESULTS: Numeric chromosomal anomalies were found in 0% (0 of 50) of benign, 20% (10 of 50) of hyperplasia, 74% (35 of 47) of atypical hyperplasia, and 87% (46 of 53) of carcinoma specimens.
  • The mean percentage of cells with chromosomal changes was 55% in cancer specimens, which was significantly higher than that in hyperplasia without atypia (13%, P < .0001) and atypical hyperplasia (32%, P = .003).
  • FISH anomalies had an overall sensitivity of 81% and specificity of 90% for the detection of atypical hyperplasia and/or endometrial carcinoma.
  • There was no association with grade of endometrial carcinoma.
  • CONCLUSIONS: Multitarget FISH appears to be useful for the differential diagnosis of hyperplasia, atypical hyperplasia, and endometrial adenocarcinoma, with a high level of sensitivity and specificity.
  • It is also a potential tool for the early detection of neoplastic cells in endometrial cytology specimens.
  • Endometrial hyperplasia with FISH-detected chromosomal anomalies may represent a clinically significant subset of cases that warrant close clinical follow-up.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Endometrial Hyperplasia / genetics. Endometrial Neoplasms / genetics. In Situ Hybridization, Fluorescence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • (PMID = 20225199.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI: Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol; 2006 Mar;107(3):701-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These data showed the following rates of pathology: 8.5% low-grade squamous intraepithelial lesions (LSIL), 11.1% high-grade squamous intraepithelial lesions (HSIL), 2.9% adenocarcinoma in situ, 1.4% endometrial hyperplasia, and 5.2% malignancy.
  • The most common malignancies were endometrial adenocarcinoma (57.6%), cervical adenocarcinoma (23.6%), ovarian and fallopian tube carcinoma (6.4%), squamous cell carcinoma of the cervix (5.4%), and other (6.9%).
  • CONCLUSION: Histologic diagnosis showed that 29.0% of these Pap tests had findings requiring follow-up or therapeutic intervention, including a 5.2% rate of malignancy.
  • Based on these findings, 99.6% of the diagnoses are within the region of surveillance when AGUS Pap tests are evaluated with colposcopy and directed biopsy, endocervical curettage, an endometrial biopsy in patients with risk factors for endometrial cancer, and pelvic examination.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Endometrial Hyperplasia / pathology. Uterine Cervical Neoplasms / pathology


71. Ioachin E: Immunohistochemical tumour markers in endometrial carcinoma. Eur J Gynaecol Oncol; 2005;26(4):363-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical tumour markers in endometrial carcinoma.
  • Endometrial adenocarcinoma is the most common malignant neoplasm of the female genital tract and, despite its relative frequency, the molecular events that contribute to the development and progression of the lesion remain poorly understood.
  • The normal human endometrium is characterized by hormone-dependent variations during the menstrual cycle.
  • This tightly controlled system is disturbed in endometrial hyperplasia and carcinomas and a series of changes initiate and promote progression towards the malignant phenotype.
  • Immunohistochemical expression of different biomarkers such as hormone receptor status (ER, PR), proliferation associated indices (PCNA, MIB1), oncogene (c-erbB-2), tumour suppressor gene products (pRb, p53 protein), cell cycle related proteins (cyclin D1, cyclin E, p21/WAF1), anti-apoptotic protein (bcl-2), adhesion molecule (CD44s), proteolytic enzyme (cathepsin D), heat shock protein (hsp27) and metallothionein (MT) has shown the contribution of these molecules to endometrial carcinogenesis in a hormone-dependent or independent manner as an early or late event.
  • In addition, these biomarkers seem to be correlated with tumour differentiation or myometrial invasion, and therefore could be considered as indicators of the biological behaviour of endometrial carcinoma.
  • Furthermore, the interrelationships of these molecular markers show that these genetic dysregulations could be implicated in the control of cell proliferation and differentiation, and thereby in the multistep process of endometrial carcinogenesis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor. Endometrial Neoplasms / diagnosis


72. Cutillo G, Cignini P, Visca P, Vizza E, Sbiroli C: Endometrial biopsy by means of the hysteroscopic resectoscope for the evaluation of tumor differentiation in endometrial cancer: a pilot study. Eur J Surg Oncol; 2007 Sep;33(7):907-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial biopsy by means of the hysteroscopic resectoscope for the evaluation of tumor differentiation in endometrial cancer: a pilot study.
  • AIMS: To assess the diagnostic accuracy of endometrial biopsy by means of the hysteroscopic resectoscope (EBHR) in evaluating tumor differentiation in patients with endometrial cancer.
  • METHODS: Between January and December 2005, all the women with a diagnosis of endometrioid adenocarcinoma of the uterus, when admitted to hospital, were enrolled for this study.
  • CONCLUSION: EBHR is a very accurate diagnostic procedure for assessing the preoperative tumor grade in patients with endometrial cancer.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrium / pathology. Hysteroscopes. Hysteroscopy / methods

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Surg Oncol. 2007 Oct;33(8):1047-8 [17336480.001]
  • (PMID = 17188830.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


73. Ilha MR, Newman SJ, van Amstel S, Fecteau KA, Rohrbach BW: Uterine lesions in 32 female miniature pet pigs. Vet Pathol; 2010 Nov;47(6):1071-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine lesions in 32 female miniature pet pigs.
  • Uterine lesions were present in all except 8 pigs.
  • The 24 remaining pigs had diffuse cystic endometrial hyperplasia, of which 14 had smooth muscle tumors, including leiomyomas and leiomyosarcomas, in the uterus or broad ligament.
  • Nodular endometrial lesions-including adenocarcinomas, adenomas, and/or adenomyosis-were present in 10 pigs, 3 of which had concurrent smooth muscle tumors.
  • In uterine sections with cystic endometrial hyperplasia, adenomyosis, or adenomas, approximately 70% of epithelial nuclei expressed estrogen receptor and progesterone receptor immunohistochemically; in adenocarcinomas, expression was 20%.
  • Aging was associated with the development of uterine lesions in miniature pet pigs.
  • [MeSH-major] Swine Diseases / pathology. Swine, Miniature / anatomy & histology. Uterine Diseases / veterinary
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / veterinary. Adenoma / pathology. Adenoma / veterinary. Animals. Broad Ligament / pathology. Endometrial Hyperplasia / pathology. Endometrial Hyperplasia / veterinary. Endometrium / pathology. Estrogens / blood. Female. Leiomyoma / pathology. Leiomyoma / veterinary. Leiomyosarcoma / pathology. Leiomyosarcoma / veterinary. Progesterone / blood. Pyometra / pathology. Pyometra / veterinary. Swine. Uterine Neoplasms / pathology. Uterine Neoplasms / veterinary. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20817893.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


74. Pozharisskiĭ KM, Vinokurov VL, Zharinov GM, Bolbarian NA, Kuznetsova ME, Gasparian NA, Samsonova EA: [Immunohistochemical markers as prognosticators in gynecologic oncology]. Vopr Onkol; 2008;54(4):463-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclooxygenase and particularly COX-2 expression impaired survival in patients operated on for endometrial adenocarcinoma of the uterus: 5-year overall and relapse-free survival in absence of expression was 92% and 88%, respectively, while in cases of distinct expression, it fell down to 52% and 48%, respectively (p = 0.0004; 0.0005).
  • The end-results of radiotherapy were associated with proliferative levels of squamous cell cervical carcinoma: for Ki-67--below median of < or = 50%, 5-year survival rate was 77%, mean survival--80 months; for Ki-67 above median of > or = 50%, the indices were 47% and 47 months, respectively, (p = 0.002).
  • [MeSH-major] Biomarkers, Tumor / analysis. Genital Neoplasms, Female / chemistry. Genital Neoplasms, Female / diagnosis. Immunohistochemistry
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adult. Aged. Cyclooxygenase 1 / analysis. Cyclooxygenase 2 / analysis. Disease-Free Survival. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Female. Gene Expression Regulation, Developmental. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Tumor Suppressor Protein p53 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18942401.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


75. Vinci A, Bacci B, Benazzi C, Caldin M, Sarli G: Progesterone receptor expression and proliferative activity in uterine tumours of pet rabbits. J Comp Pathol; 2010 May;142(4):323-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone receptor expression and proliferative activity in uterine tumours of pet rabbits.
  • Endometrial adenocarcinoma is the most common uterine tumour of domestic rabbits.
  • The present immunohistochemical study examined the expression of cytokeratin 19 (CK19), the progesterone receptor (PR), the proliferation-associated antigen Ki-67 and telomerase in normal rabbit uterine tissue and examples of endometrial hyperplasia, adenoma and adenocarcinoma.
  • Tubulopapillary adenomas and adenocarcinomas were the most common histological subtypes in this series.
  • Cytoplasmic expression of CK19 was recorded in two of three samples of normal endometrium and in one of three samples of endometrial hyperplasia, in all adenomas and five of six adenocarcinomas.
  • PR was expressed within the nucleus of normal endometrial cells and in one of three samples of endometrial hyperplasia, each of four adenomas and in four of six adenocarcinomas.
  • This finding suggests that PR expression is not directly involved in neoplastic transformation of the endometrium and that such expression is not a prognostic indicator.
  • Nuclear labelling of telomerase activity was found in one of three normal uteri, all samples of endometrial hyperplasia, two of four adenomas, but none of the adenocarcinomas.
  • The proliferation index as determined by Ki-67 expression was 9.7+/-2.75% (mean+/- standard-deviation (SD)) for normal endometrium, 11.29+/-2.5% for hyperplastic endometrium, 19.40+/-3.01% for benign tumours and 19.41+/-7.9% for malignant tumours.
  • These findings may be interpreted to suggest that hormonal and anti-proliferative treatment may be more appropriate for the management of uterine carcinomas in rabbits than anti-telomerase treatment.
  • [MeSH-major] Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Receptors, Progesterone / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / metabolism. Adenoma / pathology. Animals. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Endometrium / metabolism. Endometrium / pathology. Female. Ki-67 Antigen / metabolism. Mitotic Index. Progesterone / metabolism. Prognosis. Rabbits. Telomerase / metabolism. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology

  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20096851.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Progesterone; 4G7DS2Q64Y / Progesterone; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


76. Uchida H, Maruyama T, Nagashima T, Asada H, Yoshimura Y: Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology; 2005 Dec;146(12):5365-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.
  • In human endometrium, postovulatory production of progesterone directs estrogen-primed endometrial glandular cells to differentiate and thereby produce a number of unique bioactive substances, including glycodelin, that are critical for implantation at the secretory phase of the menstrual cycle.
  • In this study, we show that TSA and SAHA, belonging to the hydroxamic acid group of HDACIs, can induce the phenotype of a human endometrial adenocarcinoma cell line, Ishikawa (originally derived from the glandular component of the endometrium), to differentiate to closely resemble normal endometrial epithelium in a time- and dose-dependent manner, as determined by morphological changes, synthesis of glycogen, and expression of secretory phase-specific proteins, including glycodelin.
  • Furthermore, the gene silencing of glycodelin by small interference RNA resulted in the blockade of HDACI-induced differentiation in Ishikawa cells, suggesting the requirement for glycodelin for endometrial epithelial differentiation.
  • Our results collectively indicate that TSA and SAHA are potent differentiation inducers for endometrial glandular cells, providing a clue for a possible therapeutic strategy to modulate endometrial function by targeting glycodelin.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Enzyme Inhibitors / pharmacology. Glycoproteins / metabolism. Histone Deacetylase Inhibitors. Pregnancy Proteins / metabolism

  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123169.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Glycoproteins; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Interleukin-6; 0 / LIF protein, human; 0 / Leukemia Inhibitory Factor; 0 / PAEP protein, human; 0 / Pregnancy Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 3X2S926L3Z / trichostatin A; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 58IFB293JI / vorinostat; 9005-79-2 / Glycogen
  •  go-up   go-down


77. Zhang SQ, Cai B, Liu L, He YY, Yang YX, Wan XP: Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway. Int J Gynecol Cancer; 2009 Nov;19(8):1377-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway.
  • OBJECTIVE: The aim of this study was to investigate the expression of kallikrein 4 (KLK4) and the potential signal pathway through which estrogen up-regulates KLK4 in endometrial cancer.
  • METHODS: The expression of KLK4 was analyzed in 15 human normal endometrium, 13 hyperplasia endometrium, and 68 endometrioid adenocarcinoma by immunohistochemistry.
  • After exposure to 17beta-estradiol and/or to the mitogen-activated protein kinase (MAPK) inhibitor U0126 and to the PI3K inhibitor LY294002, the expression of KLK4 in the endometrial cancer cell lines KLE and RL95-2 was detected with quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and Western blot.
  • RESULTS: The expression of KLK4 protein was higher in endometroid endometrial cancer than in hyperplasia or normal endometrium (P < 0.001).
  • Immunohistochemical staining revealed that 92.6% (63/68) of endometrial adenocarcinoma, 61.5% (8/13) of hyperplasia endometrium, and 26.7% (4/15) of normal endometrium were positive for KLK4 protein.
  • Quantitative reverse transcriptase PCR and Western blot analysis showed that estrogen can up-regulate the expression of KLK4 in endometrial cancer cell lines KLE and RL95-2, and the up-regulation effect of 17beta-estradiol on KLK4 can be inhibited by U0126 in the 2 endometrial cancer cell lines but not by LY294002.
  • CONCLUSIONS: Kallikrein 4 is a new nuclear protein, and estrogen up-regulates the expression of KLK4 by activating the MAPK pathway in endometrial cancer cell lines, which may play an important role in the development of endometrial cancer.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Estradiol / pharmacology. Kallikreins / metabolism. Mitogen-Activated Protein Kinases / metabolism

  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009893.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 4TI98Z838E / Estradiol; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 4
  •  go-up   go-down


78. Burnett AF, Stone PJ, Duckworth LA, Roman JJ: Robotic radical trachelectomy for preservation of fertility in early cervical cancer: case series and description of technique. J Minim Invasive Gynecol; 2009 Sep-Oct;16(5):569-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic radical trachelectomy for preservation of fertility in early cervical cancer: case series and description of technique.
  • STUDY OBJECTIVE: To present a case series of robotic radical trachelectomy for preservation of fertility in early cervical cancer.
  • PATIENTS: Women with early cervical cancer who wish to maintain fertility potential.
  • The procedure also uses a cervical cerclage and permits preservation of the ascending branches of the uterine arteries to the uterus.
  • To date, 6 women have undergone robotic radical trachelectomy, with preservation of the uterine arteries in all patients.
  • One patient underwent completion hysterectomy when the frozen section of the trachelectomy margin revealed inability to clear the cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Gynecologic Surgical Procedures / methods. Lymph Node Excision / methods. Robotics. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19835799.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, Kwon YS, Lee IH, Lim KT, Lee KH, Shim JU, Mok JE, Kim TJ: Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer; 2009 Aug;19(6):1068-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
  • INTRODUCTION: The purpose of this study was to evaluate the efficacy of conservative treatment with progestin and pregnancy outcomes in women with early-stage endometrial cancer.
  • METHODS: We retrospectively analyzed the medical records of 35 patients with endometrial adenocarcinoma, who were treated with progestin from January 1996 to December 2006.
  • Women with early-stage grade 1 endometrioid endometrial adenocarcinoma, who wanted to receive conservative treatment or preserve fertility, were included.
  • Complete remission (CR) was defined as no evidence of endometrial adenocarcinoma or hyperplasia.
  • Partial remission was diagnosed when the patient developed endometrial hyperplasia, and persistent disease was defined as residual endometrial adenocarcinoma by pathologic confirmation.
  • CONCLUSIONS: Conservative treatment with progestin can be considered a good therapeutic option in patients with well-differentiated early-stage endometrioid endometrial adenocarcinoma who wish to preserve their uteri or become pregnant.
  • [MeSH-major] Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / rehabilitation. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / rehabilitation. Pregnancy Outcome. Progestins / therapeutic use

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820370.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Progestins; C2QI4IOI2G / Medroxyprogesterone Acetate; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


80. Papanas N, Giatromanolaki A, Galazios G, Maltezos E, Sivridis E: Endometrial carcinoma and diabetes revisited. Eur J Gynaecol Oncol; 2006;27(5):505-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma and diabetes revisited.
  • OBJECTIVE: To investigate whether endometrial adenocarcinomas are intrinsically different in diabetic as compared to non-diabetic patients.
  • METHODS: A series of 208 patients with histologically confirmed endometrial adenocarcinomas were divided into groups of diabetic (n = 63) and non-diabetic (n = 145) patients.
  • RESULTS: A history of a second neoplasia was significantly more frequent in diabetic than in non-diabetic patients (p = 0.001), but other endometrial cancer associated characteristics, such as tumor morphology, FIGO stage, obesity, hypertension, nulliparity, estrogen use and menopausal status did not differ between the groups.
  • CONCLUSIONS: A second neoplasia occurred significantly more frequently in diabetic than in non-diabetic patients with endometrial carcinoma, but long-term survival and other clinical and histological features were the same in the two groups.
  • These results indicate that endometrial adenocarcinoma is not intrinsically different in diabetic patients.
  • [MeSH-major] Adenocarcinoma / complications. Diabetes Complications. Endometrial Neoplasms / complications. Neoplasms, Second Primary / epidemiology

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Complications.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139988.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


81. Newbold RR, Jefferson WN, Grissom SF, Padilla-Banks E, Snyder RJ, Lobenhofer EK: Developmental exposure to diethylstilbestrol alters uterine gene expression that may be associated with uterine neoplasia later in life. Mol Carcinog; 2007 Sep;46(9):783-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developmental exposure to diethylstilbestrol alters uterine gene expression that may be associated with uterine neoplasia later in life.
  • Previously, we described a mouse model where the well-known reproductive carcinogen with estrogenic activity, diethylstilbestrol (DES), caused uterine adenocarcinoma following neonatal treatment.
  • Tumor incidence was dose-dependent reaching >90% by 18 mo following neonatal treatment with 1000 microg/kg/d of DES.
  • To identify molecular pathways involved in DES-initiation events, uterine gene expression profiles were examined in prepubertal mice exposed to DES (1, 10, or 1000 microg/kg/d) on days 1-5 and compared to controls.
  • Of more than 20 000 transcripts, approximately 3% were differentially expressed in at least one DES treatment group compared to controls; some transcripts demonstrated dose-responsiveness.
  • When expression profiles were compared to published studies of uteri from 5-d-old DES-treated mice, or adult mice treated with 17beta estradiol, similarities were seen suggesting persistent differential expression of estrogen responsive genes following developmental DES exposure.
  • Moreover, several altered genes were identified in human uterine adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Diethylstilbestrol / toxicity. Gene Expression / drug effects. Uterine Neoplasms / genetics. Uterus / drug effects

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • [Cites] Mol Endocrinol. 2006 Jul;20(7):1535-46 [16513791.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S11-7 [16690809.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):6-11 [12517768.001]
  • [Cites] J Midwifery Womens Health. 2003 Jan-Feb;48(1):19-29 [12589302.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:161-9 [12724221.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Aug;25(8):635-6 [12902917.001]
  • [Cites] Genome Biol. 2003;4(10):R70 [14519205.001]
  • [Cites] Mol Endocrinol. 2003 Oct;17(10):2070-83 [12893882.001]
  • [Cites] Reprod Toxicol. 2004 May;18(3):399-406 [15082075.001]
  • [Cites] Lab Anim Sci. 1999 Oct;49(5):530-6 [10551455.001]
  • [Cites] Mol Cell Endocrinol. 1999 Dec 20;158(1-2):1-5 [10630399.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):235-7 [10667565.001]
  • [Cites] Mol Hum Reprod. 2000 May;6(5):469-73 [10775652.001]
  • [Cites] Toxicol Pathol. 2000 Mar-Apr;28(2):237-45 [10805141.001]
  • [Cites] FASEB J. 2000 Jun;14(9):1101-8 [10834931.001]
  • [Cites] Histol Histopathol. 2001 Jan;16(1):131-40 [11193187.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4325-8 [11389053.001]
  • [Cites] Dev Biol. 2001 Oct 15;238(2):224-38 [11784006.001]
  • [Cites] J Mol Endocrinol. 2002 Jun;28(3):213-23 [12063187.001]
  • [Cites] Nucleic Acids Res. 2002 Aug 15;30(16):e86 [12177314.001]
  • [Cites] Exp Biol Med (Maywood). 2002 Oct;227(9):709-23 [12324652.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Cancer Causes Control. 2002 Oct;13(8):753-8 [12420954.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):142-50 [15313586.001]
  • [Cites] N Engl J Med. 1971 Apr 15;284(15):878-81 [5549830.001]
  • [Cites] J Natl Cancer Inst. 1979 Aug;63(2):507-18 [287840.001]
  • [Cites] Cancer Res. 1981 Feb;41(2):721-34 [7448817.001]
  • [Cites] Cancer Res. 1980 Nov;40(11):3988-99 [7193511.001]
  • [Cites] Science. 1981 Jun 19;212(4501):1402-4 [6262919.001]
  • [Cites] J Endocrinol. 1981 Nov;91(2):281-7 [7299327.001]
  • [Cites] Proc Soc Exp Biol Med. 1986 Jan;181(1):59-65 [3945625.001]
  • [Cites] Exp Mol Pathol. 1988 Feb;48(1):59-76 [3335252.001]
  • [Cites] Acta Anat (Basel). 1987;130(4):351-8 [3434191.001]
  • [Cites] Endocrinology. 1988 Jun;122(6):2355-63 [3286224.001]
  • [Cites] Mol Endocrinol. 1988 Sep;2(9):816-24 [3173352.001]
  • [Cites] Toxicology. 1988 Oct;51(2-3):201-12 [3176028.001]
  • [Cites] J Steroid Biochem. 1989 Mar;32(3):339-43 [2784840.001]
  • [Cites] J Biol Chem. 1989 Oct 5;264(28):16941-7 [2674144.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7677-81 [2174729.001]
  • [Cites] Mol Endocrinol. 1990 Jul;4(7):1041-50 [2126598.001]
  • [Cites] In Vitro Cell Dev Biol. 1992 May;28A(5):327-36 [1597405.001]
  • [Cites] J Natl Cancer Inst. 1993 Oct 6;85(19):1558-70 [8411230.001]
  • [Cites] Environ Health Perspect. 1993 Oct;101(5):378-84 [8080506.001]
  • [Cites] Cell Growth Differ. 1994 Jun;5(6):595-606 [8086337.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):778-88 [7717601.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):507-13 [8630958.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 1996;104(2):111-22 [8740934.001]
  • [Cites] Anat Rec. 1996 Jul;245(3):459-71 [8800404.001]
  • [Cites] Biol Reprod. 1997 May;56(5):1147-57 [9160713.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4356-9 [9331098.001]
  • [Cites] Carcinogenesis. 1997 Dec;18(12):2293-8 [9450472.001]
  • [Cites] Dev Biol. 1998 May 15;197(2):141-54 [9630742.001]
  • [Cites] Toxicol Pathol. 1999 May-Jun;27(3):325-33 [10356709.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R149-55 [15809267.001]
  • [Cites] BMC Bioinformatics. 2005;6:168 [15998470.001]
  • [Cites] Bioinformatics. 2006 May 1;22(9):1111-21 [16522673.001]
  • [Cites] Mol Endocrinol. 2005 Mar;19(3):669-82 [15591538.001]
  • (PMID = 17394237.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 ES070060-34; United States / Intramural NIH HHS / / Z99 ES999999
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 4TI98Z838E / Estradiol; 731DCA35BT / Diethylstilbestrol
  • [Other-IDs] NLM/ NIHMS40443; NLM/ PMC2254327
  •  go-up   go-down


82. Bellone S, Shah HR, McKenney JK, Stone PJ, Santin AD: Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. Am J Obstet Gynecol; 2008 Sep;199(3):e7-e10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
  • Recurrent/metastatic endometrial adenocarcinoma that is not amenable to cure with local or regional therapy and/or chemotherapy represents a discouraging clinical entity for the clinician.
  • We report the case of 58-year-old woman with recurrent endometrial carcinoma that was resistant to chemotherapy that was treated successfully with the aromatase inhibitor anastrozole.
  • [MeSH-major] Adenocarcinoma / drug therapy. Aromatase Inhibitors / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nitriles / therapeutic use. Triazoles / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18550023.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Receptors, Estrogen; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


83. Rodina AV, Sladkova LV, Obukhova VV, Vezirkhanova TZ, Moskaleva EIu, Prusakova OV, Beletskiĭ IP, Belushkina NN, Strel'nikov VV, Ivanov MA, Severin SE, Severin ES: [Inactivation and sensitization of the tumor cells by the gene Bax transfection]. Mol Biol (Mosk); 2005 Jan-Feb;39(1):40-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After the transfection of the gene Bax into the cultured tumor cells of human ovary adenocarcinoma SKOV3 and uterus carcinoma HeLa in vitro the high sensitivity of the cells SKOV3 to the protein Bax produced after the gene Bax transfection was found.
  • [MeSH-minor] Adenocarcinoma. Antibiotics, Antineoplastic / pharmacology. Cell Survival. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Female. Green Fluorescent Proteins / biosynthesis. Green Fluorescent Proteins / genetics. Humans. Liposomes. Mutation. Ovarian Neoplasms. Tumor Cells, Cultured. Uterine Cervical Neoplasms. bcl-2-Associated X Protein

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15773546.001).
  • [ISSN] 0026-8984
  • [Journal-full-title] Molekuliarnaia biologiia
  • [ISO-abbreviation] Mol. Biol. (Mosk.)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / BAX protein, human; 0 / Liposomes; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 147336-22-9 / Green Fluorescent Proteins; 80168379AG / Doxorubicin
  •  go-up   go-down


84. Karlsson S, Olsson B, Klinga-Levan K: Gene expression profiling predicts a three-gene expression signature of endometrial adenocarcinoma in a rat model. Cancer Cell Int; 2009;9:12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling predicts a three-gene expression signature of endometrial adenocarcinoma in a rat model.
  • BACKGROUND: In the Western world, endometrial cancers are the most common gynaecological neoplastic disorders among women.
  • The objective of this work was to identify a gene expression signature specific for endometrial adenocarcinomas to be used for testing potential endometrial biomarkers.
  • RESULTS: Changes in expression between endometrial adenocarcinomas and non-/pre-malignant endometrium from the BDII EAC rat model were compared in cDNA microarray assays.
  • CONCLUSION: Taken together, we present a unique data set of genes with different expression patterns between EACs and non-/pre-malignant endometrium, and specifically we found three genes that were confirmed in two independent analyses.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Cell Mol Biol. 2008 Jan;38(1):95-104 [17673689.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):657-67 [11522750.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Aug;177(1):43-50 [17693190.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4794-802 [17150964.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] Gynecol Oncol. 2005 Sep;98(3):427-33 [15993480.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Apr 15;158(2):137-41 [15796960.001]
  • [Cites] Semin Reprod Endocrinol. 1999;17(1):73-92 [10406078.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jun;5(6):411-7 [8781735.001]
  • [Cites] J Natl Cancer Inst. 1987 Jun;78(6):1245-51 [3473261.001]
  • [Cites] Z Versuchstierkd. 1987;30(5-6):209-16 [3445711.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Bioinformatics. 2004 Oct 12;20(15):2479-81 [15073010.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):649-62 [15188130.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Endocr Relat Cancer. 2003 Mar;10(1):23-42 [12653669.001]
  • [Cites] Genome Biol. 2002 Jul 15;3(8):SOFTWARE0003 [12186655.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2778-90 [12019154.001]
  • [Cites] Int J Cancer. 2001 Dec 15;94(6):795-9 [11745480.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8043-50 [17804715.001]
  • (PMID = 19426485.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2687412
  •  go-up   go-down


85. Caceres A, Mourton SM, Bochner BH, Gerst SR, Liu L, Alektiar KM, Kardos SV, Barakat RR, Boland PJ, Chi DS: Extended pelvic resections for recurrent uterine and cervical cancer: out-of-the-box surgery. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1139-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended pelvic resections for recurrent uterine and cervical cancer: out-of-the-box surgery.
  • Patients with recurrent uterine and cervical cancer have poor prognoses.
  • The objective of this study was to analyze the outcomes of patients with recurrent uterine and cervical cancer who had undergone attempted curative resection of pelvic bone, sidewall muscle, major blood vessels, and/or nerves.
  • We reviewed the records of all 14 patients with recurrent uterine and cervical cancer who had extended pelvic resections at our institution between June 2000 and November 2006.
  • Primary sites of disease were the uterus (11 patients) and cervix (3 patients).
  • Tumor histology was as follows: adenocarcinoma, seven; squamous cell carcinoma, three; leiomyosarcoma, three; and adenosarcoma, one.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Pelvic Exenteration. Uterine Cervical Neoplasms / surgery


86. Shirley S, Devi VS, Krishnamurthy R, Nabhi MV, Majhi U, Selvaluxmy G: Endometrial adenocarcinoma involving both horns of a bicornuate uterus. J Cancer Res Ther; 2010 Jul-Sep;6(3):304-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma involving both horns of a bicornuate uterus.
  • We report a rare case of endometrial adenocarcinoma involving both horns of a bicornuate uterus in a postmenopausal woman.
  • Patient underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and bilateral pelvic lymph node dissection following an initial positive diagnosis of well differentiated endometrioid adenocarcinoma on endometrial biopsy.
  • Endometrial carcinoma arising in malformed uterus is rare.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Uterus / abnormalities

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119258.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


87. Yoshida M, Watanabe G, Shirota M, Maekawa A, Taya K: Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats. J Reprod Dev; 2005 Dec;51(6):707-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats.
  • Ovarian dysfunction leading to hormonal imbalance plays a crucial role in uterine carcinogenesis in rats as well as women.
  • However, the effects of a reduction in primordial follicles at birth on uterine adenocarcinoma development have hitherto not been determined.
  • The present study was therefore conducted using female Donryu rats, a high incidence rat strain of uterine adenocarcinoma.
  • The incidence of uterine adenocarcinomas and multiplicity of uterine neoplastic lesions were significantly increased by the 5.0 mg/kg, but not the 2.5 mg/kg busulfan treatment.
  • These results provide evidence that the reduction of primordial follicles promotes uterine adenocarcinoma development in rats in association with an earlier occurrence of the persistent estrus status.
  • [MeSH-major] Adenocarcinoma / etiology. Antineoplastic Agents, Alkylating / pharmacology. Busulfan / pharmacology. Endometrial Neoplasms / etiology. Ovarian Diseases / chemically induced. Ovarian Follicle / drug effects

  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177545.001).
  • [ISSN] 0916-8818
  • [Journal-full-title] The Journal of reproduction and development
  • [ISO-abbreviation] J. Reprod. Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Gonadal Steroid Hormones; G1LN9045DK / Busulfan
  •  go-up   go-down


88. Mendivil A, Schuler KM, Gehrig PA: Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control; 2009 Jan;16(1):46-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes.
  • BACKGROUND: Understanding the etiology, presentation, evaluation, and management of selected non-endometrioid endometrial adenocarcinomas of the uterine corpus is needed to define optimal treatment regimens.
  • METHODS: The pathology and treatment of selected non-endometrioid endometrial adenocarcinomas of the uterus are reviewed and summarized.
  • RESULTS: The most common non-endometrioid histology is papillary serous (10%), followed by clear cell (2% to 4%), mucinous (0.6% to 5%), and squamous cell (0.1% to 0.5%).
  • Some non-endometrioid endometrial carcinomas behave more aggressively than the endometrioid cancers such that even women with clinical stage I disease often have extrauterine metastasis at the time of surgical evaluation.
  • Therefore, when technically and medically feasible, comprehensive surgical staging is helpful for women with non-endometrioid endometrial cancer histology.
  • While whole abdominal radiotherapy has a limited role in early-stage uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CC), there may be a role for postoperative chemotherapy and volume-directed radiotherapy in both early-stage UPSC and CC.
  • In the setting of recurrent disease or in women with residual disease after surgery, a platinum-based regimen or enrollment in a clinical trial is recommended.
  • The remaining cell types should be treated similar to endometrioid or other low-grade histologies.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19078929.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 51
  •  go-up   go-down


89. Kraft O: Incidental diagnosis of uterine cancer on 99mTc-dimercaptosuccinic acid renal scintigraphy. Hell J Nucl Med; 2005 May-Aug;8(2):132-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental diagnosis of uterine cancer on 99mTc-dimercaptosuccinic acid renal scintigraphy.
  • A computerized tomography showed a very large uterus, sized 19 x 10 cm, with myomatous nodes, calcifications and disintegration cavities.
  • Histopathology showed a myomatous uterus with an adenocarcinoma which also affected both ovaria.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Kidney / radionuclide imaging. Pyelonephritis / radionuclide imaging. Radioisotope Renography / methods. Technetium Tc 99m Dimercaptosuccinic Acid. Uterine Neoplasms / radionuclide imaging

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hell J Nucl Med. 2005 Sep-Dec;8(3):176 [16390027.001]
  • (PMID = 16142257.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 494JNQ8L28 / Technetium Tc 99m Dimercaptosuccinic Acid
  •  go-up   go-down


90. Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, Powell MA, Hendrickson MR, Kapp DS, Chan JK: Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer; 2006 Mar 13;94(5):642-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.
  • To compare the survival of women with uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CC) to those with grade 3 endometrioid uterine carcinoma (G3EC).
  • Uterine papillary serous carcinoma and CC patients were older (median age: 70 years and 68 vs 66 years, respectively; P<0.0001) and more likely to be black compared to G3EC (15 and 12% vs 7%; P<0.0001).
  • Uterine papillary serous carcinoma, CC and G3EC patients represent 10, 3, and 15% of endometrial cancers but account for 39, 8, and 27% of cancer deaths, respectively.
  • Women with UPSC and CC of the uterus have a significantly poorer prognosis compared to those with G3EC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Endometrioid / pathology. Carcinoma, Papillary / pathology. Endometrial Neoplasms / pathology. SEER Program / statistics & numerical data

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Nov 15;101(10):2214-21 [15452833.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2152-4 [15389471.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):839-44 [16199314.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):16-22 [17574073.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1117-21 [10613347.001]
  • [Cites] Gynecol Oncol. 2000 Apr;77(1):55-65 [10739691.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):166-70 [10926797.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):79-85 [12182977.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(4):300-4 [12214728.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):181-5 [12821361.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):470-5 [14675664.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] Adv Anat Pathol. 2004 May;11(3):117-42 [15096727.001]
  • [Cites] Cancer. 1973 May;31(5):1127-40 [4705150.001]
  • [Cites] Cancer. 1976 Feb;37(2):872-82 [943228.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Cancer. 1987 Oct 15;60(8 Suppl):2035-41 [3652025.001]
  • [Cites] Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):65-70 [1986629.001]
  • [Cites] Gynecol Oncol. 1991 Mar;40(3):207-17 [2013441.001]
  • [Cites] Int J Gynecol Pathol. 1995 Jan;14(1):30-8 [7883423.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1740-7 [8859187.001]
  • [Cites] Gynecol Oncol. 1997 May;65(2):206-12 [9159326.001]
  • [Cites] Gynecol Oncol. 1999 Sep;74(3):385-94 [10479498.001]
  • [Cites] Cancer. 1957 Jan-Feb;10(1):124-30 [13413808.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):593-6 [15581969.001]
  • (PMID = 16495918.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361201
  •  go-up   go-down


91. Temkin SM, Pezzullo JC, Hellmann M, Lee YC, Abulafia O: Is body mass index an independent risk factor of survival among patients with endometrial cancer? Am J Clin Oncol; 2007 Feb;30(1):8-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is body mass index an independent risk factor of survival among patients with endometrial cancer?
  • OBJECTIVE: To evaluate whether body mass index (BMI) is an independent risk factor for survival in patients with endometrial adenocarcinoma.
  • METHODS: Women treated for endometrial cancer at the State University of New York (SUNY), Downstate and Kings County Hospital between January 1982 and September 2003 were eligible.
  • Patients were divided into groups based upon their histology at the time of diagnosis.
  • The first included patients with low-grade endometrioid adenocarcinoma (FIGO grades 1 and 2); the second included grade 3 endometrioid adenocarcinoma; and the third contained papillary serous and clear cell carcinomas.
  • There were 312 patients (70%) treated for low-grade endometrial adenocarcinoma; 64 patients (14%) for grade 3 endometrioid adenocarcinoma; and 71 patients (16%) for papillary serous and clear cell adenocarcinoma.
  • BMI was also correlated to tumor grade, stage at diagnosis, age, and race.
  • Statistical analyses revealed the majority of the association between BMI and survival can be attributed to the association between BMI and these other risk factors for survival in endometrial cancer.
  • CONCLUSIONS: Increased BMI is associated with survival advantage among patients with endometrial cancer.
  • [MeSH-major] Adenocarcinoma / physiopathology. Body Mass Index. Endometrial Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278888.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Contreras CM, Gurumurthy S, Haynie JM, Shirley LJ, Akbay EA, Wingo SN, Schorge JO, Broaddus RR, Wong KK, Bardeesy N, Castrillon DH: Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res; 2008 Feb 1;68(3):759-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas.
  • Mutations in the LKB1 tumor suppressor gene result in the Peutz-Jeghers syndrome, an autosomal dominant condition characterized by hamartomatous polyps of the gastrointestinal tract and a dramatically increased risk of epithelial malignancies at other sites, including the female reproductive tract.
  • Here we show that female mice heterozygous for a null Lkb1 allele spontaneously develop highly invasive endometrial adenocarcinomas.
  • To prove that these lesions were indeed due to Lkb1 inactivation, we introduced an adenoviral Cre vector into the uterine lumen of mice harboring a conditional allele of Lkb1.
  • This endometrial-specific deletion of the Lkb1 gene provoked highly invasive and sometimes metastatic endometrial adenocarcinomas closely resembling those observed in Lkb1 heterozygotes.
  • Although Lkb1 has been implicated in the establishment of cell polarity, and loss of polarity defines most endometrial cancers, Lkb1-driven endometrial cancers paradoxically exhibit (given their highly invasive phenotype) normal cell polarity and apical differentiation.
  • In human endometrial cancers, Lkb1 expression was inversely correlated with tumor grade and stage, arguing that Lkb1 inactivation or down-regulation also contributes to endometrial cancer progression in women.
  • This study shows that Lkb1 plays an important role in the malignant transformation of endometrium and that Lkb1 loss promotes a highly invasive phenotype.
  • [MeSH-major] Adenocarcinoma / genetics. Cell Transformation, Neoplastic / genetics. Endometrial Neoplasms / genetics. Protein-Serine-Threonine Kinases / deficiency

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245476.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCRR NIH HHS / RR / K26RR024196
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multienzyme Complexes; EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / AMP-Activated Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


93. Wilson M, Hermes R, Bainbridge J, Bassett H: A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum). J Zoo Wildl Med; 2010 Mar;41(1):111-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum).
  • The rhinoceros' uterus had previously been evaluated by ultrasound and diffuse endometrial hyperplasia and two benign uterine leiomyomas had been diagnosed.
  • At necropsy examination, a large, infiltrative, metastatic uterine adenocarcinoma was found multifocally throughout the uterus, scattered within the peritoneal cavity, on the diaphragm, the splenic capsule, the pleural surface of the lung and mesenteric lymph nodes.
  • [MeSH-major] Adenocarcinoma / veterinary. Lung Neoplasms / veterinary. Perissodactyla. Peritoneal Neoplasms / veterinary. Splenic Neoplasms / veterinary. Uterine Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20722262.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Lou HM, Lou HK, Wu MJ: [Synchronous primary cancer of the endometrium and ovary]. Zhonghua Zhong Liu Za Zhi; 2006 Aug;28(8):617-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous primary cancer of the endometrium and ovary].
  • To investigate the clinical and pathological characteristics, treatment, and The data of 12 patients prognosis of synchronous primary cancer of the endometrium and ovary.
  • Methods with synchronous primary cancer of the endometrium and ovary were retrospectively reviewed .
  • Results Eight patients had the same histological type of endometrioid carcinoma in both uterus and ovary, 4 patients had different histological types in uterus and ovary.
  • Synchronous primary cancer of the endometrium and ovary was difficult to be dignosed preoperatively.
  • endometrioid carcinomas was the main pathologic type (66.7%).
  • CONCLUSION: Synchronous primary endometrium and ovary cancer is a specific kind of tumor different from either the primary endometrium carcinoma or ovary carcinoma, and usually can be detected in early stage with a good prognosis.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / therapy. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236559.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CP protocol
  •  go-up   go-down


95. Iso Y, Sawada T, Rokkaku K, Shimoda M, Kubota K: Ball-valve gastric tumor associated with anomalous junction of the pancreatico-biliary ductal system and a right-sided round ligament: report of a case. Surg Today; 2008;38(5):458-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ball-valve gastric tumor associated with anomalous junction of the pancreatico-biliary ductal system and a right-sided round ligament: report of a case.
  • We report the case of a ball-valve gastric tumor associated with anomalous junction of the pancreatico-biliary ductal system (AJPBDS) and a right-sided round ligament, misdiagnosed preoperatively as advanced gastric cancer with pancreatic head invasion.
  • Gastroscopy revealed a bleeding polypoid gastric tumor in the anterior wall of the stomach, herniating into the duodenum (ball-valve syndrome), and a Bormann type-2 tumor in the posterior wall.
  • Ultrasonography showed gallbladder stones, dilatation of the intrahepatic bile duct and pancreatic duct, and a left-sided gallbladder (attributed to a right-sided round ligament with anomalous branches of the portal veins).
  • Laparotomy revealed that the gastric tumors were not advanced cancer invading the pancreatic head.
  • [MeSH-major] Adenocarcinoma / surgery. Digestive System Abnormalities / complications. Polyps / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Round Ligament of Uterus / abnormalities

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterol Jpn. 1977;12(4):293-304 [590702.001]
  • [Cites] Gastroenterology. 1974 Aug;67(2):324-32 [4847712.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):274-80 [9060583.001]
  • [Cites] Surgery. 1985 Nov;98 (5):964-9 [4060073.001]
  • [Cites] Radiology. 1998 Jun;207 (3):723-8 [9609896.001]
  • [Cites] J Pediatr Surg. 1973 Dec;8(6):907-10 [4785564.001]
  • [Cites] Arch Surg. 1964 Mar;88:494-7 [14088282.001]
  • [Cites] Gastroenterol Jpn. 1990 Apr;25(2):249-52 [2189778.001]
  • [Cites] Am J Surg. 1946 Apr;71:505-18 [21020176.001]
  • [Cites] Ann Radiol (Paris). 1969;12(3):231-40 [5401505.001]
  • [Cites] J Pediatr Surg. 1982 Aug;17(4):359-61 [6181241.001]
  • (PMID = 18560972.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


96. Ai Z, Yin L, Zhou X, Zhu Y, Zhu D, Yu Y, Feng Y: Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer; 2006 Aug 15;107(4):746-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer.
  • BACKGROUND: Endometrial cancer is a common gynecologic malignancy among women.
  • The molecular mechanisms involved in the progression of endometrial cancer are unclear, which has hampered the development of an effective treatment.
  • METHODS: Survivin mRNA and protein expression levels were analyzed in human normal cycling endometrium, atypical endometrium, and endometrial adenocarcinoma by immunohistochemical, reverse-transcriptase polymerase chain reaction (RT-PCR), and Western blot analyses.
  • To study the biological function of survivin in endometrial cancer, RNA interference was applied to knock down survivin expression in the Ishikawa endometrial cancer cell line by recombinant plasmids producing survivin small hairpin RNA.
  • RESULTS: Higher levels of survivin mRNA and protein expression were observed in endometrial adenocarcinomas than in atypical or normal endometrium.
  • Immunohistochemical staining revealed that 83.3% (50 of 60) of endometrial adenocarcinoma samples, 55.0% (11 of 20) of atypical endometrium samples, and 25.0% (5 of 20) of normal endometrium samples were positive for survivin protein.
  • Epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha) upregulated survivin protein expression by activating the MAPK pathway in endometrial cancer cells.
  • CONCLUSIONS: Survivin is an attractive target for endometrial cancer treatment.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Cell Proliferation. Endometrial Neoplasms / pathology. Microtubule-Associated Proteins / antagonists & inhibitors. Neoplasm Proteins / antagonists & inhibitors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826583.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Cysteine Proteinase Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RNA, Small Interfering; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


97. Stewart CJ, Little L: Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition. Histopathology; 2009 Jul;55(1):91-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition.
  • AIMS: Endometrial endometrioid adenocarcinomas (EEC) may show a distinctive morphological alteration characterized by the presence of microcystic, elongated and fragmented ('MELF') glands.
  • These changes share features of epithelial-mesenchymal transition (EMT) in carcinomas arising at other sites.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Differentiation. Endometrial Neoplasms / pathology. Epithelial Cells / pathology. Immunophenotyping. Mesoderm / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614771.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / Keratin-7; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


98. Halabalaki M, Alexi X, Aligiannis N, Lambrinidis G, Pratsinis H, Florentin I, Mitakou S, Mikros E, Skaltsounis AL, Alexis MN: Estrogenic activity of isoflavonoids from Onobrychis ebenoides. Planta Med; 2006 May;72(6):488-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compounds 1 - 4 induced cell proliferation and gene expression in breast and endometrial cancer cells in an ER-dependent manner.
  • While the antiestrogen ICI 182,780 could inhibit the induction of proliferation of ER-positive breast cancer cells by 1-4, it could not prevent 1 from exhibiting significant ER-independent cytotoxicity at 10 microM.
  • By contrast, 1 was much less cytotoxic and only weakly estrogenic for ER-positive endometrial adenocarcinoma cells.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16773531.001).
  • [ISSN] 0032-0943
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Isoflavones; 0 / Phytoestrogens; 0 / Plant Extracts
  •  go-up   go-down


99. Patai K, Dévényi L, Hubay M, Patai B, Csömör S, Zelkó R: [Phosphor/sulphur ratio: indicator of malignant uterine changes]. Orv Hetil; 2006 May 28;147(21):997-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phosphor/sulphur ratio: indicator of malignant uterine changes].
  • The purpose of the present study was to find a correlation between gynaecological diseases--myoma (26), adenocarcinoma uteri (21) - and P/S (phosphor/sulphur) ratios of different regions of uterus.
  • The results of the non-parametric statistical test (Wilcoxon two-sample test) indicate that the P/S ratios were significantly higher in adenocarcinoma (0.8891 +/- 0.0757) than in myoma (0.4713 +/- 0.0306).
  • [MeSH-major] Phosphorus Compounds / metabolism. Sulfur Compounds / metabolism. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16812975.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Phosphorus Compounds; 0 / Sulfur Compounds
  •  go-up   go-down


100. Abdulhathi MB, Al-Salam S, Kassis A, Ghazal-Aswad S: Unusual presentation of cervical cancer as advanced ovarian cancer. Arch Gynecol Obstet; 2007 Oct;276(4):387-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of cervical cancer as advanced ovarian cancer.
  • We report a case of cervical adenocarcinoma presenting primarily as advanced ovarian cancer with the primary site totally silent.
  • Right salpingo-oophorectomy was performed with the histologic diagnosis of dermoid cyst.
  • Follow-up after 5 months showed a higher level of serum CA 125 (1,594 micro/ml) and a negative cervical smear.
  • Surprisingly, the histologic features of the specimen obtained at laparotomy were consistent with a moderately differentiated cervical adenocarcinoma with metastases to corpus uterus, ovaries, left fallopian tube, omentum and pleural cavity.
  • The final stage was stage IV cervical cancer.
  • CONCLUSION: Cervical carcinoma should be suspected in any patient presented with bilateral ovarian tumors and positive ascitic fluid cytology.
  • Negative cervical smears do not exclude the possibility of primary cervical carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged






Advertisement